US 20040137071A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2004/0137071 A1**

Unger (43) **Pub. Date: Jul. 15, 2004**

(54) **NANOCAPSULE ENCAPSULATION SYSTEM AND METHOD**

(75) Inventor: **Gretchen M. Unger**, Chaska, MN (US)

Correspondence Address:
PATTERSON, THUENTE, SKAAR & CHRISTENSEN, P.A.
4800 IDS CENTER
80 SOUTH 8TH STREET
MINNEAPOLIS, MN 55402-2100 (US)

(73) Assignee: **Genesegues, Inc.**

(21) Appl. No.: **10/652,814**

(22) Filed: **Aug. 29, 2003**

Related U.S. Application Data

(63) Continuation of application No. 09/796,575, filed on Feb. 28, 2001, now Pat. No. 6,632,671.

(60) Provisional application No. 60/185,282, filed on Feb. 28, 2000.

Publication Classification

(51) **Int. Cl.**[7] **A61K 33/24**; A61K 9/14

(52) **U.S. Cl.** **424/489**; 424/649

(57) **ABSTRACT**

The present invention generally relates to nanocapsules and methods of preparing these nanocapsules. The present invention includes a method of forming a surfactant micelle and dispersing the surfactant micelle into an aqueous composition having a hydrophilic polymer to form a stabilized dispersion of surfactant micelles. The method further includes mechanically forming droplets of the stabilized dispersion of surfactant micelles, precipitating the hydrophilic polymer to form precipitated nanocapsules, incubating the nanocapsules to reduce a diameter of the nanocapsules, and filtering or centrifuging the nanocapsules.



Figure 1

Figure 2A



Nanocapsules prepared under different dispersion conditions.

Figure 2B



Cumulative release studies for nanocapsule formulations.

Figure 2C



Quantitative recovery of DNA from receiver solutions.

Figure 3



Nanocapsule modulation of cellular uptake.

Figure 4



Dose response for a nanocapsule formula.

Figure 5A



Nanocapsule-delivered transgene production in porcine dermis.

Figure 5B



Macromolecule delivery across keratinized barrier epithelia.

Figure 6



Incorporation of nanocapsules into a suture coating.

Figure 7A



PVP nanocapsules are taken up by fibroblasts but not keratinocytes.

Figure 7B



Nanocapsule design for tumor-targeting.

Figure 7C



Nanocapsule coating design for increased drug safety.

Figure 8A



Cellular uptake and lysosomal sequestration of RNA oligomers complexed with polyethyleneimine.

Figure 8B



Nanocapsules avoid lysosomal sequestration at 18 hours postaddition.

NANOCAPSULE ENCAPSULATION SYSTEM AND METHOD

CROSS-REFERENCE TO RELATED APPLICATION(S)

[0001] This application is a continuation of application Ser. No. 09/796,575 filed Feb. 28, 2001, which claims the benefit of U.S. Provisional Application No. 60/185,282 filed Feb. 28, 2000.

BACKGROUND OF THE INVENTION

[0002] The present invention generally relates to a field of controlled-release delivery systems for macromolecules, particularly those for nucleic acids and gene therapy. More specifically, the present invention relates to nanocapsules having a diameter of less than about 50 nanometers, in which a bioactive component is located in a core of the nanocapsule, and to methods of forming these nanocapsules.

[0003] Over the past several decades, active and extensive research into the use of nanoparticles in the delivery of bioactive agents has generated a number approaches in the preparation of nanoparticles. These approaches typically include the use of heat, high pressure homogenization, or high intensity ultrasound sonication to prepare nanoparticles having a diameter of more than 100 nanometers, or high amounts of solvents or oils, cytotoxic chemicals, such as cross-linking agents, adjuvants, catalysts or any combination of any of these, to prepare nanoparticles having a diameter of less than 100 nanometers. Furthermore, these approaches are challenging due to a number of variables.

[0004] For example, when organic solvents are included in the manufacturing process for nanoparticles, the organic solvent may denature the bioactive agent which reduces most, if not all, efficacy of the bioactive agent. In fact, denaturation of the bioactive agent may promote a toxic response upon administration of the nanoparticle, to a human subject, for example.

[0005] In addition, when an organic solvent is used to prepare nanoparticles, the organic solvent may undergo degradation to form a low pH environment that destroys the efficacy of the bioactive agent. Therefore, organic

[0006] As a result, organic solvents are typically removed during the manufacturing process of nanoparticles. However, inclusion of one or more organic solvent removal techniques generally increases the costs and complexity of forming nanoparticles.

[0007] The incorporation of high pressure homogenization or high intensity ultrasound sonication to prepare nanoparticles typically results in entangling or embedding the bioactive agent in a polymeric matrix of the nanoparticle. Entangling or embedding the bioactive agent in the polymeric matrix may also denature the bioactive agent to thereby reduce the efficacy of the bioactive agent.

[0008] Entangling or embedding the bioactive agent in the polymeric matrix of the nanoparticle may also reduce the efficacy of the bioactive agent by permitting premature release of the bioactive agent prior to reaching a target cell. Premature release of the bioactive agent typically promotes cytotoxicity or cell death during administration of the nanoparticle.

[0009] Furthermore, nanoparticles that reach the target cell are typically transported into the target cell via endosomal regulated pathways that results in lysosomal degradation of the bioactive agent and the nanoparticle. Therefore, functional activity of the bioactive agent inside the target cell may not occur since the bioactive agent and the nanoparticle undergoes degradation. As used herein, the term "functional activity" refers to an ability of a bioactive agent to function within a target cell for purposes of providing a therapeutic effect on the target cell.

[0010] Additionally, high pressure homogenization or high intensity ultrasound sonication techniques often require complex and expensive equipment that generally increases costs in preparing nanoparticles. Therefore, an urgent need exists to prepare nanoparticles without the use of cytotoxic chemicals like organic solvents or the use of complex and expensive equipment. Furthermore, an urgent need exists to prepare nanoparticles that do not entangle nor embed the bioactive agent in the nanoparticle so that cytotoxic responses are minimized. Additionally, an urgent need exists to develop a nanoparticle that maybe transported into a target cell where the bioactive agent is released to accomplish therapeutic delivery of the bioactive agent.

BRIEF SUMMARY OF THE INVENTION

[0011] The present invention generally relates to nanocapsules and methods of preparing these nanocapsules. The present invention includes a method of forming a surfactant micelle and dispersing the surfactant micelle into an aqueous composition having a hydrophilic polymer to form a stabilized dispersion of surfactant micelles. The method further includes mechanically forming droplets of the stabilized dispersion of surfactant micelles, precipitating the hydrophilic polymer to form precipitated nanocapsules, incubating the nanocapsules to reduce a diameter of the nanocapsules, and filtering or centrifuging the nanocapsules.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] **FIG. 1** is a schematic of a method of the present invention for preparing nanocapsules.

[0013] **FIG. 1A** illustrates atomic force microscopy of nanocapsule formulations prepared under different dispersion conditions.

[0014] **FIG. 1B** illustrates results from an experiment documenting quantitative recovery of small amounts of DNA from releasing solutions.

[0015] **FIG. 1C** illustrates cumulative release over 72 hours for nanocapsules prepared under different dispersion conditions.

[0016] **FIG. 2** illustrates relative pinocytotic activity of HacaT keratinocyte cultures treated with DNA complexes, nanocapsules containing DNA or no treatment.

[0017] **FIG. 3** illustrates the results of western blotting of total protein from rat fibroblast cultures.

[0018] **FIG. 4A** illustrates

[0019] **FIG. 4B** illustrates immunofluorescence microscopy of porcine dermal tissue sections from the experiment of **FIG. 4**.

[0020] **FIG. 5** shows incorporation of nanocapsules into a solid dosage form.

[0021] **FIG. 6A** illustrates polyvinylpyrolidone nanocapsule uptake and Green Fluorescent Protein (GFP) expression in 35 mm human dermal fibroblast and immortalized keratinocyte cultures.

[0022] **FIG. 6B** illustrates tumor targeting of GFP plasmid DNA by Tenascin nanocapsules.

[0023] **FIG. 6C** illustrates an effect of nanocapsules that are coated with Tenascin and nanocapsules that are not coated with Tenascin on growth inhibition of squamous cell carcinoma and human dermal fibroblast (HDF) cultures.

[0024] **FIG. 7** shows uptake of HDF cultures treated with nanocapsules containing 20 mer Fitc-labeled O-methyl RNA oligonucleotides.

DETAILED DESCRIPTION

[0025] The present invention generally relates to nanocapsules having a diameter of less than about 50 nanometers (nm). The present invention also relates to a method of preparing these nanocapsules. According to the method of the present invention, a nanocapsule is formed by partitioning a bioactive component within a core of surfactant molecules, and surrounding the surfactant molecules with a biocompatible polymer shell.

[0026] A method for producing the nanocapsule is generally depicted at **10** in **FIG. 1**. In the method **10**, a bioactive component **12** is homogeneously dispersed into a first aqueous composition **14** to form a hydrophilic composition (not shown). Next, a surfactant composition **16**, including a surfactant component (not shown) that contains a plurality of surfactant molecules, and an optional biocompatible oil component **18**, are introduced into a first dispersing apparatus **20** along with the hydrophilic composition. The surfactant composition **16** is subjected to conditions in the first dispersing apparatus **20** that initiate at least partial adsorption of the surfactant molecules onto a surface of the bioactive component **12**.

[0027] Partial adsorption of surfactant molecules onto the surface of the bioactive component **12** initiates partitioning of the bioactive component **12** into a core of a shell formed from the surfactant molecules in the first aqueous composition **14**. Adsorption of the surfactant molecules onto the surface of the bioactive component **12** may proceed until an entire surface of the bioactive component **12** is covered by the surfactant molecules to complete partitioning of the bioactive component **12** into the core of surfactant molecules and form a surfactant micelle **22**.

[0028] Next, a biocompatible polymer component **24** is added to the surfactant micelle **22** to stabilize the surfactant micelle **22** located in the first aqueous composition **14**. Preferably, the biocompatible polymer component **24** surrounds the surfactant micelle **22** in a stabilizing apparatus **26** to form a stabilized surfactant micelle **28**.

[0029] After stabilization, the stabilized surfactant micelle **28** is transferred from the stabilizing apparatus **26** into a second aqueous composition **30** located in a second dispersing apparatus **32**. Preferably, the second aqueous composition **30** includes a solute (not shown) that is capable of precipitating the biocompatible polymer component **24** that coats the stabilized surfactant micelle **28**. After precipitating the biocompatible polymer component **24** of the stabilized surfactant micelle **28**, dispersed, optionally atomized precipitated nanocapsules **36**, hereinafter referred to as nanocapsules **36**, are formed.

[0030] It has been discovered that dispersing a surfactant composition, that includes a surfactant component having a hydrophile-lipophile-balance (HLB) value of less than about 6.0 units, into an aqueous composition that contains a bioactive component forms surfactant micelles that surround the bioactive component. It has further been discovered that stabilizing the surfactant micelles by adding a biocompatible polymer coats the surfactant micelles to form nanocapsules having a diameter of less than about 50 nm.

[0031] As used herein, the term "nanoparticle" refers a particle having a matrix-type structure with a size of less than about 1,000 nanometers. When the nanoparticle includes a bioactive component, the bioactive component is entangled or embedded in the matrix-type structure of the nanoparticle.

[0032] The term "nanosphere", as used herein, refers to a particle having a solid spherical-type structure with a size of less than about 1,000 nanometers. When the nanosphere includes a bioactive component, the bioactive component is adsorbed onto the surface of the nanosphere or embedded in the nanosphere.

[0033] Similarly, the term "nanocore", as used herein, refers to a particle having a solid core with a size of less than about 1,000 nanometers. When the nanocore includes a bioactive component, the bioactive component is entangled in the nanocore.

[0034] As used herein, the term "nanocapsule" refers to a particle having a hollow core that is surrounded by a shell, such that the particle has a size of less than about 1,000 nanometers. When a nanocapsule includes a bioactive component, the bioactive component is located in the core that is surrounded by the shell of the nanocapsule. The term "nanocapsule" is not meant to encompass, and generally does not include, a particle having a size of less than about 1,000 nanometers, in which a bioactive component is entangled or embedded in the matrix of the nanocapsule or adsorbed onto the surrounding shell of the nanocapsule.

[0035] The bioactive component **12** may be included into the first aqueous composition **14** as a liquid, vapor or in granular form. The form of the bioactive component **12** that is selected preferably permits the bioactive component **12** to (1) remain stable prior to dissolving or dispersing into the first aqueous composition **14**, (2) be homogeneously dispersed into the first aqueous composition **14**, (3) be optionally condensed to reduce a size of the bioactive component **12**, (4) be partitioned into the core of the surfactant micelles **22**, (5) be released upon degradation of the biocompatible polymer shell **24** of the nanocapsule **36**, and (6) be functionally active upon release from the nanocapsule **36**.

[0036] The bioactive component **12** may be characterized as "hydrophilic" or "hydrophobic". As used herein, the term "hydrophilic" and "hydrophilicity" refers to an ability of a molecule to adsorb water or form one or more hydrogen-bond(s) with water. All references to "hydrophilic" is also understood as encompassing any portion of the molecule that is capable of adsorbing water or forming one or more

hydrogen-bond(s) with water. As used herein, the term "hydrophobic" and "hydrophobicity" refers to an ability of a molecule to not adsorb water nor form one or more hydrogen-bond(s) with water. All references to "hydrophobic" is also understood as encompassing any portion of the molecule that is not capable of adsorbing water nor forming one or more hydrogen-bond(s) with water.

[0037] When the bioactive component **12** is a hydrophilic bioactive component, the hydrophilic bioactive component maybe directly added to the first aqueous composition **14**. As an alternative, the hydrophilic bioactive component **12** may be optionally dissolved or dispersed in one or more solvents, such as water, a nonpolar solvent, a polar solvent, or any combination of any of these.

[0038] As used herein, the term "nonpolar solvent" refers to a solvent that does not have a permanent electric dipole moment, and therefore has no ability for an intramolecular association with a polar solvent. Additionally, a nonpolar solvent may be characterized as a solvent that includes molecules having a dielectric constant of less than about 20 units. Similarly, the term "immiscible", as used herein, refers to an inability of two or more substances, such as two or more liquids, solids, vapors, or any combination of any of these, to form an intramolecular association with another substance. Some non-exhaustive examples of nonpolar solvents may be found in Perry's Chemical Engineer's Handbook, Sixth Edition, which is incorporated herein by reference.

[0039] As used herein, the term "polar solvent" refers to a solvent that has a permanent electrical dipole moment, and therefore has an ability to form an intramolecular association with another polar substance, such as a liquid, a solid, a vapor or any combination of any of these. Additionally, a polar solvent may be characterized as a solvent that includes molecules having a dielectric constant of more than about 20 units. Likewise, the term "miscible", as used herein, refers to an ability of two or more substances to form an intramolecular association with each other. Some non-exhaustive examples of polar solvents may be found in Perry's Chemical Engineer's Handbook, Sixth Edition, which has been incorporated herein by reference.

[0040] When the bioactive component **12** is a hydrophobic bioactive component, the hydrophobic bioactive component may be dispersed or dissolved in a solvent that is capable of dispersing or dissolving the hydrophobic molecule, such as the above-mentioned water, a nonpolar solvent, a polar solvent, or any combination of any of these. Preferably, when the bioactive component **12** is a hydrophobic bioactive component **12**, the hydrophobic bioactive component **12** is dissolved or dispersed in a water-miscible solvent, such as, acetone, acetonitrile, ethanol, dimethyl acetamide (DMA), tetrahydrofuran (THF), dioxane, dimethylsulfoxide (DMSO), and dimethylformamide (DMF). Other suitable non-exhaustive examples of water-miscible solvents may be found in Perry's Chemical Engineer's Handbook, Sixth Edition, which has been incorporated herein by reference.

[0041] As noted, the bioactive component **12** may be optionally condensed in the first aqueous composition **14** prior to forming the surfactant micelle **16**. For example, when the bioactive component is a polynucleotide, the polynucleotide may be condensed using a DNA-condensing agent. As used herein, a "DNA-Condensing Agent" is a molecule that facilitates condensation or a size reduction of DNA.

[0042] While condensation of the bioactive component **12** is not critical to the present invention, condensation of the bioactive component **12** maybe practiced to reduce the size of the bioactive component **12**. Condensation of the bioactive component **12** generally reduces the size of the bioactive component **12** prior to partitioning into the core of the surfactant micelle **16**. Reducing the size of the bioactive component **12** may permit maximum incorporation of the bioactive component **12** into the surfactant micelle **22** or may assist a reduction in the overall size of the nanocapsule **36**. Increasing the amount of the bioactive component **12** that may be included as part of the nanocapsule **36** permits incorporation of macromolecules having a large number of monomers, such as a large number of base pairs or amino acids, for example. Some non-exhaustive examples of condensing agents have been reviewed in Rolland, A. P. (1998). *Crit. Rev. Therapeutic Drug. Carr. Syst.* 15:143-198, and is incorporated herein by reference.

[0043] The bioactive component **12** may further include additional components that are compatible with, and that do not interfere with solvation or dispersion of the bioactive component **12**. Some non-exhaustive examples of additional components that may be added to the bioactive component **12** include a DNA-associating moiety, which refers to a molecule, or portions thereof, that interact in a non-covalent fashion with nucleic acids. DNA-associating moieties may include, but are not limited to, a major-and minor-groove binder, a DNA intercalator, a polycation, a DNA-masking component, a membrane-permeabilizing component, a subcellular-localization component, or the like. Major- and minor-groove binders, as used herein, are molecules thought to interact with DNA by associating with the major or minor groove of double-stranded DNA.

[0044] Similarly, the term "DNA intercalator", as used herein, refer to a planar molecule or planar portion of a molecule thought to intercalate into DNA by inserting themselves between, and parallel to, a nucleotide base pair. As used herein, a "polycation" is thought to associate with the negative charges on the DNA backbone. The DNA-associating moiety may be covalently linked through a "reactive group" to a functional component of this invention. The reactive group is easily reacted with a nucleophile on the functional component. Some non-exhaustive examples of reactive groups (with their corresponding reactive nucleophiles) include, but are not limited to N-hydroxysuccinimide (e.g., amine), maleimide and maleimidophenyl (e.g., sulfhydryl), pyridyl disulfide (e.g., sulfhydryl), hydrazide (e.g., carbohydrate), and phenylglyoxal (e.g., arginine).

[0045] The term "DNA-masking component", as used herein, refers to a molecule capable of masking all or part of a polynucleotide following release from a nanocapsule to increase its circulatory half-life by inhibiting attack by degrading reagents, such as nucleases, present in the circulation and/or interfering with uptake by the reticuloendothelial system. Similarly, the term "membrane-permeabilizing component", as used herein, refers to any component that aids in the passage of a polynucleotide or encapsulated polynucleotide across a membrane. Therefore, "membrane

permeabilizing component" encompasses in part a charge-neutralizing component, usually a polycation, that neutralizes the large negative charge on a polynucleotide, and enables the polynucleotide to traverse the hydrophobic interior of a membrane.

[0046] Many charge-neutralizing components can act as membrane-permeabilizers. Membrane-permeabilization may also arise from amphipathic molecules. A "membrane permeabilizer", as used herein, is a molecule that can assist a normally impermeable molecule to traverse a cellular membrane and gain entrance to the cytoplasm of the cell. The membrane permeabilizer may be a peptide, bile salt, glycolipid, phospholipid or detergent molecule. Membrane permeabilizers often have amphipathic properties such that one portion is hydrophobic and another is hydrophilic, permitting them to interact with membranes.

[0047] The term "subcellular-localization component", as used herein, refers to a molecule capable of recognizing a subcellular component in a targeted cell. Recognized subcellular components include the nucleus, ribosomes, mitochondria, and chloroplasts. Particular subcellular-localization components include the "nuclear-localization components" that aid in carrying molecules into the nucleus and are known to include the nuclear localization peptides and amino acid sequences.

[0048] The bioactive component **12** may be included at an amount that is therapeutically effective to transform a plurality of cells, such as in vitro, in vivo or ex vivo cells. As used herein, "transform" refers to a presence and/or functional activity of the bioactive component in the plurality of cells after exposing the nanocapsules to the plurality of cells.

[0049] Furthermore, those of ordinary skill in the art will recognize that the amount of the bioactive component **12** may vary depending upon the bioactive component **12**, the temperature, pH, osmolarity, any solutes, any additional component or optional solvents present in the second aqueous component **30**, the surfactant composition **16**, a type or an amount of the surfactant micelle **22**, the biocompatible polymer component **24**, any desired characteristics of the stabilized surfactant micelle **28**, any desired characteristics of the nanocapsules **36**, or any combination of any of these.

[0050] The bioactive component **12** of the nanocapsule **36** maybe supplied as an individual macromolecule or supplied in various prepared mixtures of two or more macromolecules that are subsequently combined to form the bioactive component **12**. Some non-exhaustive examples of hydrophilic macromolecules that may be suitable for inclusion as part of the bioactive component **12** include, but are not limited to polynucleotides, polypeptides, genetic material, peptide nucleic acids, aptamers, carbohydrates, mini-chromosomes, molecular polymers, aggregates or associations of an inorganic or organic nature, genes, any other hydrophilic macromolecule or any combination of any of these.

[0051] Some non-exhaustive examples of hydrophobic macromolecules that may be included part of the bioactive component **12** include, but are not limited to, adregergic, adrenocotical steroid, adrenocortical suppressant, aldosterone antagonist, and anabolic agents; analeptic, analgesic, anesthetic, anorectic, and anti-acne agents; anti-adrenergic, anti-allergic, anti-amebic, anti-anemic, and anti-anginal agents; anti-arthritic, anti-asthmatic, anti-atherosclerotic, antibacterial, and anticholinergic agents; anticoagulant, anti-convulsant, antidepressant, antidiabetic, and antidiarrheal agents; antidiuretic, anti-emetic, anti-epileptic, antifibrionlytic, and antifungal agent; antihemorrhagic, inflammatory, antimicrobial, antimigraine, and antimiotic agents; antimycotic, antinauseant, antineoplastic, antineutropenic, and antiparasitic agents; antiproliferative, antipsychotic, antirheumatic, antiseborrheic, and antisecretory agents; antipasmodic, antihrombotic, antiulcerative, antiviral, and appetite suppressant agents; blood glucose regulator, bone resorption inhibitor, bronchodilator, cardiovascular, and cholinergic agents; fluorescent, free oxygen radical scavenger, gastrointestinal motility effector, glucocorticoid, and hair growth stimulant agent; hemostatic, histamine H2 receptor antagonists; hormone; hypocholesterolemic, and hypoglycemic agents; hypolipidemic, hypotensive, and imaging agents, immunizing and agonist agents; mood regulators, mucolytic, mydriatic, or nasal decongestant; neuromuscular blocking agents; neuroprotective, NMDA antagonist, non-hormonal sterol derivative, plasminogen activator, and platelet activating factor antagonist agent; platelet aggregation inhibitor, psychotropic, radioactive, scabicide, and sclerosing agents; sedative, sedative-hypnotic, selective adenosine A1 antagonist, serotonin antagonist, and serotonin inhibitor agent; serotonin receptor antagonist, steroid, thyroid hormone, thyroid hormone, and thyroid inhibitor agent; thyromimetic, tranquilizer, amyotrophic lateral sclerosis, cerebral ischemia, and Paget's disease agent; unstable angina, vasoconstrictor, vasodilator, wound healing, and xanthine oxidase inhibitor agent; immunological agents, antigens from pathogens, such as viruses, bacteria, fungi and parasites, optionally in the form of whole inactivated organisms, peptides, proteins, glycoproteins, carbohydrates, or combinations thereof, any examples of pharmacological or immunological agents that fall within the above-mentioned categories and that have been approved for human use that may be found in the published literature, any other hydrophobic bioactive component, or any combination of any of these.

[0052] As used herein, the term "polypeptide" refers to a polymer of amino acids not limited by the number of amino acids. It is also to be understood that the term "polypeptide" is meant to encompass an oligopeptide, a peptide, or a protein, for example.

[0053] As used herein, the term "polynucleotide" refers to RNA or DNA sequences of more than 1 nucleotide in either single chain, duplex or multiple chain form. The term "polynucleotide" is also meant to encompass polydeoxyribonucleotides containing 2'-deoxy-D-ribose or modified forms thereof, RNA and any other type of polynucleotide which is an N-glycoside or C-glycoside of a purine or pyrimidine base, or modified purine or pyrimidine base or basic nucleotide. The polynucleotide may encode promoter regions, operator regions, structural regions, termination regions, combinations thereof or any other genetically relevant material. Similarly, the term "genetic" as used herein, refers to any material capable of modifying gene expression.

[0054] The first aqueous composition **14** may be included in the method of the present invention as a gel, liquid, or in vapor form. The form of the first aqueous composition **14** that is selected preferably permits the first aqueous composition **14** to (1) remain stable prior to dissolving or dispersing the bioactive component, the surfactant composition **16**,

the surfactant micelle **22**, or optionally the stabilizer surfactant micelle **28**, (2) homogeneously disperse the bioactive component **12**, the surfactant composition **16**, the surfactant micelle **22**, or optionally the stabilizer surfactant **28**, (3) function as a continuous phase in an oil-in-water emulsion, (4) not interfere with, or mask the functional activity of the bioactive component **12**, and (5) not modify or degrade the bioactive component **12**, the surfactant composition **16**, the surfactant micelle **22**, or optionally the stabilized surfactant micelle **28**.

[**0055**] The first aqueous composition **14** may include only water, or may optionally include additional solutes or solvents that do not interfere with the method of forming the nanocapsules **36** nor mask the functional activity of the bioactive component **12**. Furthermore, those of ordinary skill in the art will recognize that an amount of the first aqueous composition **14** used to prepare the nanocapsules **36** may vary depending upon the bioactive component **12**, the surfactant composition **16**, the temperature, pH, osmolarity, optional solutes or optional solvents, the surfactant micelle **22**, the biocompatible polymer component **24**, any desired characteristics of the stabilized surfactant micelle **28** or the nanocapsules **36**.

[**0056**] The bioactive component **12** may be added to the first aqueous composition **14** or the first aqueous composition **14** may be added to the bioactive component **12**. While the order of addition of the bioactive component **12** and the first aqueous composition **14** is not critical to the present invention, the hydrophilic composition (not shown) that is formed when the bioactive component **12** is dissolved or dispersed in the first aqueous composition **14** is preferably capable of maintaining a homogeneous solution or dispersion in the hydrophilic composition.

[**0057**] The first aqueous composition **14** may be supplied as an individual component or supplied in various prepared mixtures of two or more components that are subsequently combined to form the first aqueous composition **14**. Some non-exhaustive examples of the first aqueous composition **14** include, but are not limited to, the above-mentioned water, nonpolar solvents, polar solvents, or any combination of any of these. Preferably, water is the first aqueous composition **14**.

[**0058**] The surfactant composition **16** maybe introduced into the bioactive component **12**, the first aqueous composition **14**, the hydrophilic composition as a liquid, vapor or in granular form. The form of the surfactant composition **16** that is selected preferably permits the surfactant composition **16** to (1) remain stable prior to introducing into the bioactive component **12**, the first aqueous composition **14**, or the hydrophilic composition, (2) be homogeneously dispersed into the bioactive component **12**, the first aqueous composition **14**, or the hydrophilic composition, (3) form a micellar structure, (4) be adsorbed onto a surface of the bioactive component **12**, the first aqueous composition **14**, the hydrophilic composition (5) displace the first aqueous composition that is located on the surface of the bioactive component **12**, (6) partition the bioactive component **12** or the hydrophilic composition into a core of the micellar structure to form the surfactant micelle **22**, and (7) provide a thermodynamic driving force that is effective to reduce a size of the bioactive component **12**, surfactant micelle **22**, the stabilized surfactant **28** or the nanocapsule **36**.

[**0059**] As used herein, a "surfactant" refers to any molecule containing a polar portion that thermodynamically prefers to be solvated by a polar solvent, and a hydrocarbon portion that thermodynamically prefers to be solvated by a non-polar solvent. The term "surfactant" is also meant to encompass anionic, cationic, or non-ionic surfactants. As used herein, the term "anionic surfactant" refers to a surfactant with a polar portion that ionizes to form an anion in aqueous solution. Similarly, a "cationic surfactant" refers to a surfactant having a cationic polar portion that ionizes to form a cation in aqueous solution. Likewise, a "non-ionic" surfactant refers to a surfactant having a polar portion that does not ionize in aqueous solution.

[**0060**] While not wanting to be bound to theory, it is generally believed that a surfactant refers to a molecule that is effective to reduce a surface or an interfacial tension between a first substance dispersed in a second substance such that the first substance is solvated and any molecular groups of the first substance are dispersed. Typically, a hydrodynamic diameter of the first substance increases after addition of the surfactant. Nonetheless, the surfactant composition **16** is believed to be effective to reduce the size or diameter of the surfactant micelles **22** in the first aqueous composition **14**, to thereby reduce the size of the nanocapsule **36** when practicing the present invention.

[**0061**] The surfactant composition **16** may include the surfactant component only (not shown), or may optionally include the biocompatible oil component **18**. The surfactant component may be characterized on the HLB scale that ranges from less than about 1 to more than about 13 units.

[**0062**] A surfactant component having an HLB value of less than about 6.0 units may be described as being poorly, or not dispersable in an aqueous or water-based composition. In addition, a surfactant component having an HLB value of less than about 6.0 units may be characterized as a hydrophobic or non-ionic surfactant. A surfactant component having an HLB value of more than about 7.0 units may be described as being capable of forming a milky to translucent to clear dispersion when the surfactant having an HLB value of more than about 7.0 units is dispersed in an aqueous or water-based composition.

[**0063**] Preferably, the surfactant component of the surfactant composition **16** has an HLB value of less than about 6.0 units when practicing the method of the present invention. Still more preferably the surfactant component of the surfactant composition **16** has an HLB value of less than about 5.0 units to facilitate preparation of nanocapsules having a diameter of less than about 50 nm.

[**0064**] The surfactant component may also be characterized in terms of a critical micelle concentration (CMC) value. Preferably, the surfactant component of the surfactant composition **16** has a CMC value of less than about 300 micromolars (μm). Still more preferably, the surfactant component has a CMC value of less than about 200 μm.

[**0065**] While not wanting to be bound to theory, it is believed that the surfactant component of the surfactant composition **16** adsorbs onto the surface of the bioactive component **12** when introduced into the first aqueous composition **14** to minimize exposure of a surface of the hydrophobic surfactant component to a thermodynamically unfavorable environment created by the first aqueous

composition **14**. Therefore, the surfactant component adsorbs onto the surface of the bioactive component to reduce the surface area of the surfactant component that may be exposed to the first aqueous composition **14**. Adsorption of the surfactant component onto the bioactive component **12** is believed to facilitate the size reduction of the bioactive component **12** and/or the surfactant micelle **22**.

[**0066**] The surfactant component of the surfactant composition **16** may be supplied as individual surfactants or supplied in various prepared mixtures of two or more surfactants that are subsequently combined to form the surfactant composition 16. Some non-exhaustive examples of suitable surfactants having an HLB value of less than about 6.0 units or a CMC value of less than about 200 μm be listed in *Dermatological Formulations* (Barry, B., Marcel Dekker, (1983)), or in *Percutaneous absorption: drug, cosmetics, mechanisms, methodology,* 3rd ed., Bronough, R. ed., 1999, or the *Handbook of Industrial Surfactants* (Ash, M., Ed., Gower Pub. (1993), which are incorporated herein by reference. As an example, the surfactant component maybe 2, 4, 7, 9-tetramethyl-5-decyn-4, 7-diol(TM-diol), blends of 2, 4, 7, 9-tetramethyl-5-decyn-4, 7-diol(TM-diol), molecules having one or more acetylenic diol groups, cetyl alcohol or any combination of any of these.

[**0067**] The optional biocompatible oil component **18** of the surfactant composition **16** may be combined with the surfactant component as a liquid, vapor or in granular form. The form of the optional biocompatible oil component **18** that is selected preferably permits the optional biocompatible oil component **18** to (1) remain stable prior to introduction into the surfactant composition **16**, (2) be homogeneously blended into the surfactant composition **16**, (3) dissolve or disperse the surfactant component, and (4) increase the hydrophobicity of the surfactant composition **16**, and therefore, the degree to which the size of the bioactive component **12**, the surfactant micelle **22**, the stabilizer surfactant micelle **28**, or the nanocapsule **36** may be reduced when practicing the present invention.

[**0068**] Preferably, the concentration of the optional biocompatible oil component **18** in the surfactant composition **16** ranges from about 10^{-7} weight percent to about 10 weight percent, based upon a total volume of the stabilized surfactant micelles **28** in the first aqueous composition **14**. Concentrations of the optional biocompatible oil component **18** higher than about 10 weight percent, based upon the total volume of the surfactant composition **18**, may be less desirable because such higher concentrations increase a phase volume of the biocompatible oil, and consequently may cause difficulties in preparing, dispersing and/or handling the surfactant micelles **22**, the stabilized surfactant micelles **28** or the nanocapsules **36**. Concentrations of the optional biocompatible oil component lower than about 10^{-7} weight percent in the surfactant composition **16** may be less preferred, because such lower concentrations would not be effective to solvate the surfactant component, or increase the hydrophobicity of the surfactant composition **16**, and may ultimately increase the diameter of the nanocapsules **36**.

[**0069**] The optional biocompatible oil component **18** of the surfactant composition **16** may be supplied as an individual biocompatible oil or supplied in various prepared mixtures of two or more biocompatible oils that are subsequently combined to form the optional biocompatible oil component **18**. Some non-exhaustive examples of suitable biocompatible oils that may be included as part of the biocompatible oil component **18** may be found in *Dermatological Formulations* (Barry, B., Marcel Dekker, (1983)), or in *Percutaneous absorption: drug, cosmetics, mechanisms, methodology,* 3rd ed., Bronough, R. ed. , 1999, or in the *Handbook of Industrial Surfactants* (Ash, M., Ed., Gower Pub. (1993), which have been incorporated herein by reference. Preferably, food or USP grade oils, such as DMSO, DMF, castor oil, or any combination thereof, are used to practice the present method.

[**0070**] The surfactant composition **16** may be included at an amount that is effective to form the micellar structure that partitions the bioactive component **12**, the first aqueous composition **14** or the hydrophilic composition into the core of the micellar structure when forming the surfactant micelle **22**. Still more preferably, the surfactant composition **16** is included at an amount that is effective to provide a maximum thermodynamic driving force that minimizes the size of the bioactive component **12**, the surfactant micelle **22**, and ultimately, the size of the nanocapsule **36** when practicing the present invention.

[**0071**] Furthermore, those of ordinary skill in the art will recognize that the amount of the surfactant composition **16** may be varied based upon the bioactive component **12**, the first aqueous composition **14**, a ratio of the surfactant component to the optional biocompatible oil **18**, any desired characteristics of the surfactant micelles **22**, the stabilized surfactant micelles **28** or the nanocapsules **36**. For example, a surfactant composition containing a surfactant component having an HLB value of about 6.0 units mixed with a nonpolar biocompatible oil like castor oil, may provide the same degree of a thermodynamic driving force as a second surfactant composition containing a surfactant component of about 4.0 units mixed with DMSO.

[**0072**] The amount of the surfactant composition **16** may range up to about 0.5 weight percent, based upon a total volume of the stabilized surfactant micelles dispersed in the first aqueous composition **14**. Still more preferably, the amount of the surfactant composition **16** is less than about 0.25 weight percent, based upon the total volume of the stabilized surfactant micelles **28** dispersed in the first aqueous composition **14**. Most preferably, the surfactant composition **16** is present at an amount of less than about 0.05 weight percent, based upon the total volume of the stabilized surfactant micelles **28** dispersed in the first aqueous composition **14**. As one non-exhaustive example, the surfactant composition **16** may be added to the total volume of the hydrophilic composition at a concentration of about 500 ppm, based on the total volume of the stabilized surfactant micelles **28** in the first aqueous composition **14**.

[**0073**] The first dispersing apparatus **20** initiates and promotes formation of the micellar structures that are based on the bioactive component **12**, the first aqueous composition **14** and the surfactant composition **16**. Adsorption of surfactant component onto the surface of the bioactive component **12**, or hydrophilic composition continues until all of the surfactant molecules cover, and therefore, entrap the bioactive component **12** or hydrophilic composition in the core of the micellar structure to form surfactant micelles **22**. Formation of a plurality of surfactant micelles **22** in the first aqueous composition **14** forms a dispersion of surfactant micelles **22**.

[0074] In general, any conventional dispersing apparatus **20** that is capable of homogenously blending or dispersing may be suitable for use in forming the dispersion of surfactant micelles in accordance with the present invention. Furthermore, those of ordinary skill in the art will recognize that the first dispersing apparatus **20** may vary depending upon the desired characteristics of the nanocapsules **36**. For example, the first dispersing apparatus **20** may include any device, such as a sonicating or a vortexing apparatus (not shown), or the like to disperse the bioactive component **12** in the hydrophilic composition, and the formation of the surfactant micelles **22** after addition of the surfactant composition **16**. Nonetheless, while the first dispersing apparatus **20** may include a sonicating or a vortexing apparatus, the sonicating or the vortexing apparatus is not critical when practicing the method of the present invention.

[0075] As used herein, a "surfactant micelle" may be characterized as a close packed mono-molecular barrier of surfactant molecules at an interface between the bioactive composition **12** and the surfactant composition **16**, such that the barrier encapsulates the bioactive component **12**, the first aqueous composition **14** or the hydrophilic composition. It is also to be understood that the term "surfactant micelle" encompasses partial or hemi-surfactant micelles that partially enclose the bioactive component **12**, the first aqueous composition **14** or the hydrophilic composition.

[0076] When the bioactive component **12** is a hydrophilic bioactive component, the polar portion of the surfactant molecule associates with a surface of the hydrophilic bioactive component. When the bioactive component **12** is a hydrophobic bioactive component, the hydrocarbon portion of the surfactant micelle associates with a surface of the hydrophobic bioactive component.

[0077] The formation of a surfactant micelle typically occurs at a well defined concentration known as the critical micelle concentration. As noted, surfactant components having a CMC value of less than about 200 micromolars are preferred when practicing the present invention.

[0078] After forming the dispersion of surfactant micelles **22**, the dispersion of surfactant micelles **22** is transferred into the stabilizing apparatus **26** where a biocompatible polymer component **24** is added to stabilize the dispersion of surfactant micelles **22**. Alternatively, the biocompatible polymer component **24** may be added to the dispersion of surfactant micelles **22** in the first dispersing apparatus **20** which obviates the need for the stabilizing apparatus **26**.

[0079] The biocompatible polymer component **24** stabilizes the dispersion of surfactant micelles **22** to form stabilized surfactant micelles **28** within the first aqueous composition **14**. Therefore, a dispersion of stabilized surfactant micelles **28** are present within the first aqueous composition **14** after addition of the biocompatible polymer component **24**.

[0080] As used herein, the term "biocompatible" refers to a material that is capable of interacting with a biological system without causing cytotoxicity, undesired protein or nucleic acid modification or activation of an immune response.

[0081] The biocompatible polymer component **24** may be introduced into the dispersion of surfactant micelles **22** as a liquid, vapor or in granular form. The form of the biocompatible polymer component **24** that is selected preferably permits the biocompatible polymer component **24** to (1) remain stable prior to addition into the dispersion of surfactant micelles **22**, (2) be homogeneously dispersed into the dispersion of surfactant micelles **22**, (3) increase a viscosity of the first aqueous composition **14**, (4) form a boundary layer at an interface of the surfactant micelle **22** and the first aqueous composition **14**, (5) be absorbed onto a surface of the surfactant micelles **22**, (6) be capable of iontophoretic exchange, (7) be capable of being precipitated upon addition of a solute, (8) be capable of enzymatic degradation, surface and/or bulk erosion, (9) not interfere with or mask the functional activity of the bioactive component **12**, (10) prevent aggregation and/or agglomeration of the dispersion of surfactant micelles **22**, and (11) be capable of obtaining a particular dissolution profile.

[0082] The biocompatible polymer component **24** may be included at an amount that is effective to coat and therefore stabilize the surfactant micelle **22**. Furthermore, those of ordinary skill in the art will recognize that the amount of the biocompatible polymer component **24** used to stabilize the surfactant micelles **22** may vary depending upon the bioactive component **12**, the first aqueous composition **14**, the surfactant composition **16**, the temperature, pH, osmolarity, presence of any optional solutes or optional solvents, the surfactant micelle **22**, any desired characteristics of the stabilized surfactant micelle **28**, the nanocapsules **36**, or a desired dissolution profile.

[0083] While the concentration of the biocompatible polymer component **24** is not critical to the present invention, the concentration of the biocompatible polymer component **24** is preferably based upon the bioactive component and on the desired dissolution profile. When the concentration of the biocompatible polymer component **24** is to high, the shell of the nanocapsule **36** may not dissolve. If the concentration of the biocompatible polymer component **24** is to low, the shell of the nanocapsule **36** may dissolve rapidly in a manner that promotes cytotoxicity, for example. In addition, too low a concentration of the biopolymer component **24** may not provide an effective degree of mechanical force to stabilize the surfactant micelles **28**.

[0084] Concentrations of the biocompatible polymer component **24** that are to high may also be less desirable because such higher concentrations may increase the viscosity of the first aqueous composition **14**, and consequently may cause difficulties in preparing, mixing and/or transferring the stabilizer surfactant micelles **28**. Concentrations of the biocompatible polymer component **24** that are to low may be less preferred, because lower concentrations may not provide the needed viscosity to stabilize the surfactant micelles, nor be capable of effectively coating the surfactant micelles **22** to prevent aggregation of the surfactant micelles **22** in the first aqueous composition **14**.

[0085] The biocompatible polymer component **24** may be supplied as individual biocompatible polymers or supplied in various prepared mixtures of two or more biocompatible polymers that are subsequently combined to form the biocompatible polymer component **18**. Some non-exhaustive examples of biocompatible polymers include polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides,

polyvinylpyrrolidone, polyglycolides, polysiloxanes, polyurethanes and copolymers thereof, alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, polymers of acrylic and methacrylic esters, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxy-propyl methyl cellulose, hydroxybutyl methyl cellulose, cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetage phthalate, carboxylethyl cellulose, cellulose triacetate, cellulose sulphate sodium salt, poly(methyl methacrylate), poly(ethylmethacrylate), poly(butylmethacrylate), poly(isobutylmethacrylate), poly(hexlmethacrylate), poly(isodecylmethacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), polyethylene, polypropylene poly(ethylene glycol), poly(ethylene oxide), poly(ethylene terephthalate), poly(vinyl alcohols), poly(vinyl acetate, poly vinyl chloride polystyrene, polyvinylpryrrolidone, polyhyaluronic acids, casein, gelatin, glutin, polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates), poly(ethyl methacrylates), poly(butylmethacrylate), poly(isobutylmethacrylate), poly(hexlmethacrylate), poly(isodecl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecl acrylate) and combination of any of these.

[0086] Additionally, biocompatible polymers that have been modified for enzymatic degradation, or change upon application of light, ultrasonic energy, radiation, a change in temperature, pH, osmolarity, solute or solvent concentration may also be included as part of the biocompatible polymer component **24**. Preferably, the biocompatible polymer component **24** is a hydrophilic polymer that is capable of substantially coating, and preferably continuously coating the surfactant micelle **22**. Still more preferably, the hydrophilic biocompatible polymer component **24** is capable of ionotophoretic exchange.

[0087] Though descriptions of the present invention are primarily made in terms of a hydrophilic biocompatible polymer component **24**, it is to be understood that any other biocompatible polymer, such as hydrophobic biocompatible polymers may be substituted in place of the hydrophilic biocompatible polymer, in accordance with the present invention, while still realizing benefits of the present invention. Likewise, it is to be understood that any combination of any biocompatible polymer may be included in accordance with the present invention, while still realizing benefits of the present invention.

[0088] In general, any conventional apparatus and technique that is suitable for permitting the biocompatible polymer component **24** to stabilize the surfactant micelles **22** may be used as the stabilizing apparatus **26** in accordance with the present invention. Furthermore, any other device, such as high pressure homogenization or high ultrasound sonication is preferably not included during stabilization.

[0089] After stabilizing the surfactant micelles **22**, the stabilized surfactant micelles **28** may be transferred into a second aqueous composition **30** located in a second dispersing apparatus **32**. The stabilized surfactant micelles **28** may be transferred by mechanically forming droplets of the stabilized surfactant micelle **28** that are subsequently introduced into the second aqueous composition **30**.

[0090] The second aqueous composition **30** may include water only, or may optionally include a solute to precipitate the biocompatible polymer component **24** surrounding the stabilized surfactant micelle **28**. Some non-exhaustive examples of solutes that may be used to precipitate the biocompatible polymer **24** include ionic species derived from elements listed in the periodic table.

[0091] Preferably, the second aqueous composition **30** includes a solute in an amount that is effective to precipitate the biocompatible polymer component **24** and form the dispersed, and optionally atomized nanocapsules **36** of the present invention. As used herein, the term "precipitate" refers to a solidifying or a hardening of the biocompatible polymer component **24** that surrounds the stabilized surfactant micelles **28**. It is also to be understood that the term "precipitation" is also meant to encompass any crystallization of the biocompatible polymer **24** that may occur when the biocompatible polymer component **24** is exposed to the solute.

[0092] Additionally, any other component that is capable of modulating the efficacy the nanocapsules **36** may be included as part of the second aqueous composition to thereby modulate the functional activity of the nanocapsule **36**. For example, the second aqueous composition may include additional coating excipients, such as a cell recognition component or various ionic species, such as Mn^{2+}, Mg^{2+}, Ca^{2+}, Al^{3+}, Be^{2+}, Li^{30}, Ba^{2+}, Gd^{3+}, or any other ionic species that is capable of interacting with the biocompatible polymer component 24.

[0093] The term "cell recognition component", as used herein, refers to a molecule capable of recognizing a component on a surface of a targeted cell. Cell recognition components may include an antibody to a cell surface antigen, a ligand for a cell surface receptor, such as cell surface receptors involved in receptor-mediated endocytosis, peptide hormones, and the like.

[0094] It has been observed that when the stabilized surfactant micelles **28** are allowed to incubate in the second aqueous composition **30** that includes the solute to precipitate the biocompatible polymer component **24**, the nanocapsules **36** undergo a reduction in size. Furthermore, the formation of a flocculated suspension of the nanocapsules **36** has also been observed after incubating the stabilized surfactant micelles **28** in the second aqueous composition.

[0095] As used herein, "a flocculated suspension" refers to the formation of a loose aggregation of discrete particles held together in a network-like structure either by physical absorption of bioactive components, bridging during chemical interaction (precipitation), or when longer range van der Waals forces of attraction exceed shorter range forces of repulsion. The flocculated suspension of nanocapsules **36** may entrap varying amounts of the first aqueous composition **14** or the second aqueous composition **30** within the network-like structure. Additionally, the flocculated suspension of nanocapsules may be gently tapped to disperse the nanocapsules **36**.

[0096] The stabilized surfactant micelles **28** may be transferred into the second aqueous composition **30** via atomization through a nozzle (not shown) having a particular orifice size or through an aerosolizing apparatus (not shown). Atomizing or aerosolizing the stabilized surfactant

micelles **28** typically includes the application of a shear force that may be capable of further dispersing the stabilized surfactant micelles **28**. Furthermore, the application of the shear force during transfer may also be effective to (1) reduce the size of the nanocapsules **36**, or (2) break up any agglomerates or associations between stabilized surfactant micelles **28** that may have formed in the stabilizing apparatus **26**. Nozzle pressures of less than about 100 psi, for example, may be used to atomize the stabilized surfactant micelles **28**.

[**0097**] The diameter of the nanocapsules **36** may also be varied depending upon the orifice size of the nozzle that may be used to transfer the stabilized surfactant micelles **28** into the second aqueous composition. Alternatively, the stabilized surfactant micelles **28** may be added to the second aqueous composition **30** containing the solute that precipitates the biocompatible polymer **24** to form a dispersion of nanocapsules **36** for purposes of providing the dispersion for sub-cutaneous delivery of the nanocapsules, for example.

[**0098**] After precipitating and/or optionally incubating the nanocapsules **36** in the second aqueous composition 30, the nanocapsules **36** may be filtered, centrifuged or dried to obtain separate and discrete nanocapsules **36**. The nanocapsules **36** may be frozen or reconstituted for later use or may be delivered to a target cell or tissue by such routes of administration as oral, intravenous, subcutaneous, intraperitoneal, intrathecal, intramuscular, inhalational, topical, transdermal, suppository (rectal), pessary (vaginal), intra urethral, intraportal, intrahepatic, intra-arterial, intra-ocular, transtympanic, intraumoral, intrathecal, or any combination of any of these.

[**0099**] The nanocapsules **36** having a diameter of less than about 50 nm are advantageous in the delivery of bioactive components to target cells for several reasons. First, nanocapsules **36** having a diameter of less than about 50 nm enhances delivery of bioactive components by protecting the bioactive components against degradation during transport to the target cell.

[**0100**] Second, nanocapsules **36** having a diameter of less than about 50 nm promotes efficient cellular uptake. Efficient cellular uptake into the target cell typically occurs when a particle has a diameter of less than about 50 nm, as opposed to when a particle has a diameter of more than about 50 nm.

[**0101**] Third, it is believed that uptake of the nanocapsules **36** by the target cell occurs via transport systems, such as a non-endosomal pathway, that prevents lysosomal degradation of the nanocapsules **36**. Indeed, it is believed that the nanocapsules **36** of the present invention are efficiently exported into a cell via a caveolin-regulated pathway that circumvents most, if not all, endosomal-regulated pathways that typically degrade nanocapsules **36**.

[**0102**] Fourth, the nanocapsules **36** have a biocompatible polymer shell that is separate from the bioactive component. In fact, the bioactive component is not entangled in, embedded in, or adsorbed onto the biocompatible polymer shell of the nanocapsules **36**. When the bioactive component is not entangled in, embedded in, or adsorbed onto the biocompatible polymer shell, the cell that incorporate the nanocapsules **36** avoid apoptosis or cell death.

[**0103**] Fifth, enclosing the bioactive component within a core surrounded by the biocompatible polymer shell when preparing the nanocapsules **36** in accordance with the present method is advantageous in avoiding premature degradation of the nanocapsules **36**, or a cytotoxic response during in vivo transport of the nanocapsule. Enclosing the bioactive component within the core results in a linear release rate of the bioactive component without any zero burst phenomenon during release from the nanocapsules **36**.

[**0104**] The linear release rate of the bioactive component from the nanocapsule without any zero burst phenomenon is also an advantageous feature as the linear release rate allows rational design of coating dissolution profiles to minimize cytotoxicity. As used herein, the term "dissolution profile" refers to a rate at which the biocompatible polymer shell is dissolved or degraded to release a bioactive agent from a core of a nanocapsule.

[**0105**] Another benefit of the nanocapsules **36** prepared by the method of the present invention is that little, if any, addition of an organic solvent is required to form the nanocapsules **36**. Eliminating the use of most, if not all, organic solvents from the method of the present invention is beneficial since organic solvents may damage the bioactive component **12**, destroy the target cells, or be toxic during preparation of the nanocapsule **36**. The elimination of most, if not all, use of organic solvents eliminates the need for complex solvent removal techniques, such as solvent dilution, vacuum evaporation, or the like, and obviates any associated costs or complex process strategies during preparation of the nanocapsules **36**.

[**0106**] The nanocapsules **36** of the present invention further permits stable encapsulation of a bioactive component, and in particular, hydrophilic bioactive components, such as polynucleotides and polypeptides. "Stable encapsulation", as used herein, refers to maintenance of the encapsulated bioactive component's structure. For nucleic acids, the appearance of low molecular weight nucleic acid breakdown products, which may be assayed for by electrophoresis, is substantially eliminated. The nanocapsules **36** may also be used to encapsulate any bioactive component regardless of water solubility or charge density.

APPLICATIONS

[**0107**] The nanocapsules **36** may be combined with additional polymeric binders, surfactants, fillers, and other excipients to incorporate the nanocapsules **36** into solid dosage forms such as granules, tablets, pellets, films or coatings for use in enhanced bioactive component **12** delivery. In this way, design of the dissolution profile, control of the particle size, and cellular uptake remains at the level of the nanocapsule. Such applications include, but are not limited to, creation of rapidly dissolving nanocapsule pellets for pulmonary delivery or nanocapsule films for device-mediated delivery.

[**0108**] In another application, the nanocapsules **36** may be designed for specific cellular or tissue uptake by polymer selection and/or inclusion of cell-recognition components in the nanocapsule biocompatible polymer shell or coating. Such coatings will have utility for specific or increased delivery of the bioactive agent to the target cell. Such applications include, but are not limited to tumor-targeting of chemotherapeutic agents or anti-sense DNA, antigen delivery to antigen-presenting cells, ocular delivery of

ribozymes to retinal cells, transdermal delivery of protein antibodies, or transtympanic membrane delivery of peptide nucleic acids.

[0109] Property Determination and Characterization Techniques

[0110] Various analytical techniques are employed herein. An explanation of these techniques follows:

[0111] **FIG. 1**A: Samples were prepared on freshly cleaved mica as dispensed, dried in air and imaged using a Nanoscope II multimode AFM (Digital Instruments) with a J type scanner and ambient tapping mode holder. 125 μm long silicon cantilevers type IBMSC were from IBM and have resonant frequencies of 250-450 kHz. All imaging was in tapping mode, images were 512×512 pixels and scanning frequency was 1 kHz. Height, amplitude and phase images were collected. Images were processed in DI software and analyzed in NIH Image SXM. A: Formula Q from 2-phase system, low HLB surfactant, B: Formula S from 2-phase system, high HLB surfactant, C: Formula T from 1-phase system, high HLB surfactant, D: Formula V from 2-phase system, surfactant below CMC.

[0112] **FIG. 1**B: Nanocapsules were released into a solution of 10% isobutanol in Phosphate-buffered Saline (PBS), pH=7.2. Samples were run in duplicate. **FIG. 1**C: Nominal 300 ng samples of DNA were aliquoted from a master batch containing surfactant and processed through commercial miniprep columns. Eluate was recycled through Qiaquik columns and collected either 3 times (4, 5) or twice (6,7) or recycled through Zymoclean columns and collected twice (8,9). Samples were alcohol precipitated using a commercial coprecipitant, electrophoresed on 1.5% agarose gels modified with Synergel, stained with SybrGold dye, digitized on a Storm 860 and compared to unmodified but reprecipitated samples from the same master batch (10,11). Lanes 1-3: 100, 50 and 5 ng of ?_DNA.

[0113] **FIG. 2**: Endocytic activity was assessed by immunosignal levels of clathrin (Chemicon). Potocytotic activity was assessed by immunosignal for caveolin-1 as described in the literature (Transduction Laboratories). Lysosomal activity was detected by an monoclonal antibody to Lamp-1 (Transduction Laboratories). Nanocapsule localization was detected by streptavidin-biotin immunocomplexes directed against sheep IgG (Jackson Laboratories). Nanocapsule coatings were spiked with ovine IgG to enable this detection strategy.

[0114] **FIG. 3**: immortalized Rt-1 fibroblast cultures at 70% confluence were treated for 4 days with increasing amounts of nanocapsule formula K and transiently treated (3 hours) with an optimized liposomal formula (dose, 500 ng) Results are expressed as a percentage of cellular actin integrated intensity and compared to the liposomal formula. Expression vector was code 448: pEF/myc-his/GFP (Invitrogen).

[0115] **FIG. 4**A: Radiated porcine biopsies were snapfrozen 7 days after treatment with saline or 6 μg of controlled release nanocapsules, then homogenized in RIPA. 100 μg lysate samples were electrophoresed on SDS-Page gradient gels, transferred to nitocellulose membranes and detected for either §-galactosidase (121 Kd) or involucrin (~100 kD) using chemiluminescence. Results were normalized to the post-transfer gel stained with Coomassie due to interference at 100 kD from a gel defect. Involucrin, a component of the cornified membrane, manufactured by suprabasal cells can be detected in radiated porcine skin and will be used for future normalization purposes. Lane A: N, topical, biopsy oc-2; B: N, topical, biopsy oc-3; C: 0, topical, biopsy 1-1; D: PBS only, biopsy 1-5; E: N, subcutaneous injection, biopsy 1-6.

[0116] **FIG. 4**B: The β-galactosidase reporter protein was detected by a monoclonal antibody directed at an incorporated fusion protein tag. A: N, topical, biopsy oc-1, detection with anti-Xpress[a]; B: Matching view to A with detection for anti-von Willenbrand factor (Sigma);C: untreated biopsy, detection with anti-Xpress[a](Invitrogen).

[0117] **FIG. 5**: Nanocapsules were incorporated into an aqueous suture coating and sutures were applied to pigskin biopsies in organ culture. Nanocapsules were detected with Cy3 conjugated-streptavidin-biotin complexes to incorporated ovine IgG and GFP transgene expression was detected by rabbit polyclonal antibodies to GFP (Abcom) in combination with Fitc-conjugated polyclonal antibodies to rabbit IgG and Alexa 488-conjugated polyclonal antibodies to Fitc (Molecular Probes). Controls omitting primary antibodies were included for signal-to-background level estimation.

[0118] **FIG. 6**A: Nanocapsules were detected as previously described and GFP transgene expression was detected by rabbit polyclonal antibodies to GFP in combination with Cy3-conjugated antibodies to rabbit IgG (Jackson Laboratories).

[0119] **FIG. 6**B: GFP expression was detected as described in **FIG. 5** and cell nuclei were counterstained with 10 μg/ml bisbenzamide.

[0120] **FIG. 6**C: Carcinoma cells and HDF's were seeded overnight into 96 well plates at 2000 and 6000 cells per well respectively. Cisplatin preparations were added to wells for 18 hours as noted on the graph than washed out. After 72 hours cell viability of assessed by a commercial MTT assay (WST assay, Boehringer Mannheim). Wells were executed in duplicate.

[0121] **FIG. 7**: Colocalization with lysosomes was detected using a monoclonal antibody to Lamp-1 (Transduction Laboratories). AFM images are included of O-methyl RNA formulated by nanoencapsulation or complexation with 27 KD polyethyleneimine.

EXAMPLES

[0122] The present invention is more particularly described in the following Examples which are intended as illustrations only since numerous modifications and variations within the scope of the present invention will be apparent to those skilled in the art.

[0123] Reagents:

[0124] A. Nucleic acid condensing agents

[0125] Poly(ethylenimine) (PEI) at 27 KiloDalton (kD). PEI was used at optimized conditions (90% charge neutralization)

[0126] Polylysine (PLL) at 70-150,000 molecular weight. PLL condensing materials were conjugated with nuclear signal localization peptides, either SV-40 T antigen or cys-

gly-tyr-gly-pro-lys-lys-lys-arg-lys-val-gly-gly using carboxiimide chemistry available from Pierce Chemical (Rockford, Ill.).

[0127] Preparations of nuclear matrix proteins (NMP). NMP were collected from a rat fibroblast cell line, and a human keratinocyte cell line using a procedure described in Gerner et al. *J. Cell. Biochem.* 71 (1998):363-374 which is incorporated herein by reference. Protein preparations were conjugated with nuclear signal localization peptides as described.

[0128] B. Surfactants

[0129] 2, 4, 7, 9 - tetramethyl-5-decyn-4, 7 - diol (TM-diol): HLB=4-5, CMC is not determined

[0130] Poly(oxy-1, 2-ethanediol), a-(4-nonylphenol)-w-hydroxy, Tergitol NP-40 (NP40): HLB=17.8, CMC 180 μM,

[0131] Polyoxyethylene 20 sorbitan monooleate (Tween 80): HLB=10, CMC 920 μM, Cetyl Alcohol: HLB=4,CMC is not determined.

[0132] C. Polymers

[0133] Hyaluronan, bacterially-derived, 1 million kiloDalton (MM kD) and conjugated with nuclear localization signal peptides as described in U.S. Pat. No. 5,846,561, which is incorporated herein by reference.

[0134] Hyaluronan, derived from human umbilical cord, about 4MMKD and not conjugated.

[0135] Povidone (polyvinylpyrolidone, PVP) 10,000 kD MW and not bioconjugated Povidone (polyvinylpyrolidone, PVP) 40,000 Kd MW and not bioconjugated Povidone (polyvinylpyrolidone, PVP) 360,000 kD MW and not bioconjugated Tenascin, 220 kD and not bioconjugated.

[0136] D. Expression Vectors

[0137] 334: pcDNA/His/LacZ, produces galactosidase, incorporates CMV promoter, based on pcDNA 3.1. (Invitrogen), 8.6 kB

[0138] 425: pEGFP-c/farn, enhanced GFP (green fluorescent protein) expression vector modified with a farnasyl moiety to improve microscopy, CMV promoter, 4.6 kB

[0139] 423: pEGFP-c3/p57(Kpn/Sma) Clontech enhanced GFP (green fluorescent protein) expression vector modified with a nuclear localization tag from a cyclin dependent kinase to improve microscopy, 4.6 kB

[0140] E. Cells

[0141] CCRL 1764: Immortalized rat neonatal fibroblast cell line

[0142] HaCaT: immortalized human keratinocyte cell line

[0143] Ca9: human tumor cells derived from a squamous cell carcinoma of tongue origin.

Example 1A—Effect of changing dispersion conditions on hydrophillic nanocapsules.

[0144] The importance of appropriate dispersion conditions was investigated in the following series of formulations. Formulae were produced by i) predispersing 25 μg of DNA (425) on ice using a bath sonicator, ii) condensing DNA in a small amount of water by vortexing then incubating on ice for 20 minutes, iii) adding surfactant then oil followed by 30 seconds of probe sonication at 10 Watts, iv) diffusion dilution to 3 milliliters (mL) by first adding saline then 1 MM kD hyaluronan polymer (1%) as a protective colloid, v) mechanically shearing emulsion into droplets by pumping through a 250 micrometer (μm) orifice into 22 mL of PBS, 10 milliMolar (mM) Ca^{2+}, 200 mM Li^{+}, vi) incubating overnight end over end and vii) centrifuging to recover nanoparticles for resuspension and filter sterilization. The condenser-to-DNA weight ratio was determined by dye exclusion at 90% charge neutralization. TM-diols were used in this experiment to represent water-immiscible surfactants, while Tergitol NP40 and Tween 80 were used to represent water-soluble and even more water-soluble emulsifiers/dispersing aids.

[0145] Dispersion conditions were systematically varied to discourage micelle formation in aqueous media by i) choosing water-soluble surfactants (Formulae S,T,U, and V), ii) removing the dispersed phase (Formula T) and iii) decreasing surfactant loading below that required for micelle formation. Formula U featured use of a water-miscible oil (silicone oil).

[0146] Formulas were characterized physically and tested for functionality in in vitro gene transfer. Quantitative results are summarized in Table 1A:

TABLE 1A

Effect of changing dispersion conditions on hydrophillic nanocapsules.

	Formula		
	Q	R	S
Experimental Modification:	surf > CMC	surf > CMC	surf > CMC
Critical Micelle Concentration (CMC)	~0	~0	360 ppm
Pre-aerosol surfactant Concentration (3 ml basis)	500 ppm	500 ppm	600 ppm
HLB number	4–5	4	17.8
Phases	Water/ misc. oil	Water/ misc. oil	Water/ misc. oil
Formula Characteristics:			
Nucleic Acid Incorporation (%)	86 ± 8	67 ± 1.4	50.3 ± 12
Low MW DNA Appearance (% above bkground, Post nanocapsule digest by electrophoresis)	15.00	76	93.00
Supercoil retention (post 100 hrs release) (area %, initial distribution = 76% supercoiled)	87%	65%	66%
Particle Size (mean ± SE)	42 ± 2	45 ± 3	73 ± 4
Secondary Structure(s)	25%	30%	70%
Flocculation Status	100–200 nm stringy flocs	500 nm stringy flocs	300 nm spheroid aggregates
Comments: Performance:			
Transduced GFP Protein Generation	420	340	0

TABLE 1A-continued

Effect of changing dispersion conditions on hydrophillic nanocapsules.			
	Formula		
	Q	R	S
(pixel units, % of control liposome formula, 100 μg total protein, Day 11)			

[0147]

TABLE 1A

Effect of changing dispersion conditions on hydrophillic nanocapsules.

	Formula			
	T	U	W	V
Experimental Modification:	surf > CMC	surf > CMC	surf > CMC	surf < CMC
Critical Micelle Concentration (CMC)	360 ppm	360 ppm	1200 ppm	360 ppm
Pre-aerosol surfactant Concentration (3 ml basis)	600 ppm	600 ppm	4000 ppm	90 ppm
HLB number	17.8	17.8	10	17.8
Phases	Water only	Water/immisc. oil	Water/misc. oil	Water/misc. oil
Formula Characteristics:				
Nucleic Acid Incorporation (%)	39 ± 1.7	32.8 ± 6	37 ± 1.41	57.6 ± 16
Low MW DNA Appearance (% above bkground, Post nanocapsule digest by electrophoresis)	53.00	66	28	41.00
Supercoil retention (post 100 hrs release) (area %, initial distribution = 76% supercoiled)	59%	43%	65%	80%
Particle Size (mean ± SE)	226 ± 11 S < 10%	291 ± 25 S < 10%	150 ± 7 S > 40%	199 ± 11 S > 80% 400 nm
Secondary Structure(s) Flocculation Status			yeast-like aggregates	aggregates
Comments:	ppt. during aerosolization		ppt. during aerosolization	ppt. during aerosolization
Performance: Transduced GFP Protein Generation (pixel units, % of control liposome formula, 100 μg total protein, Day 11)	0	0	0	0

[0148] Nanocapsule sizing was determined by tapping mode AFM and images are illustrated in **FIG. 1A**. The data indicate average nanocapsule sizes less than 50 nm are achievable only with multi-phase systems in combination with low water solubility surfactants (Table 1A: Formulae Q,R vs. S,T,U,V, and W). Furthermore, only nanocapsules of less than 50 nm resulted in detectable transgene production in CRL-1764 rat fibroblast cells (Table 1A). Effective dispersion also corresponded with decreased aggregation and enhanced DNA stability (as indicated by decreased electrophoretic breakdown products). The starting DNA was partially relaxed (76% supercoiled by electrophoresis). Using this value as a basis, supercoil retention in DNA still

encapsulated following 100 hrs of release testing, was excellent in multi-phase systems.

[0149] Release profiles for hydrophillic dispersed atomized nanocapsules were linear, showed no zero burst and resulted in about 60% release after 72 hours (See **FIG. 1B**). Formula W, manufactured with the most water-soluble surfactant in the series (Tween 80) failed to completely release loaded DNA. **FIG. 1C** illustrates that small amounts of DNA (in this case 300 nanograms of DNA) can be recovered accurately in a procedure comprising butanol extraction of 10% butanol/saline releasing fluid followed by isolation on a miniprep column and measurement of absorbance at 260 nm excitation. Results obtained from UV spectroscopy are confirmed by electrophoresis of recovered DNA following alcohol coprecipitation with a commercial coprecipitant aid. Experiment 1A demonstrates the importance of a multiphase system in creating coated particles from the micellar solution, defines surfactant requirements and validates method for measuring in vitro release profiles.

Example 1B—Effect of process parameters on particle functionality

[0150] To investigate the effect of modulating process parameters on nanocapsule functionality for DNA delivery, a series of formulas (designed to release in 3 days) were prepared and measured transduction efficiency of these formulas for delivering a nuclear Green Fluorescent Protein (GFP) reporter transgene in rat fibroblast cultures 5 days later. Charge neutralization of the DNA molecule, the surfactant/oil system, total surfactant phase volume, the inclusion of probe sonication, the absolute requirement for atomization and receiving bath osmolality were modulated. Results for this experiment are summarized in the Table 1B:

[0151] Aqueous dispersion of DNA condensates with poorly soluble surfactants in the inventive method produced average nanocapsule diameters under 50 nm. A 30 number of successful operating regimes were feasible with varying effects on encapsulation yield. In a cetyl alcohol/castor oil system, under condensation resulted in an average particle diameter increase from 20 to 12 nm (Table 1B: F1vs. F2). The same decrease in condenser weight ratio induced a particle size increase from 24 to 36 nm, while still maintaining nanocapsule functionality for trangene delivery, when using a TM-diol/DMSO surfactant system for initial micelle formation (Table 1B: F4 vs. F5). This finding teaches surfactant selection impacts final average nanocapsule diameters.

[0152] Moderate energy input was removed (dropped probe sonication, atomization but kept bath sonication) during nanocapsule formation and resulted in functional particles with decreased yield (Table 1B: F3 vs. F4). This finding indicates that optimal nanocapsule production is not dependent on any spontaneous micro-emulsification process. Cosolvent phase volume was reduced from 4 weight percent to 500 ppm without any negative effect on particle functionality (Table 1B: F4 vs. F6). This finding indicates that essentially solvent-free nanocapsules can be made by the inventive method. Finally, salt was removed from the atomization receiving bath without any negative effects on nanocapsule functionality (Table 1B: F6 vs. F7).

Example 2—Effect of nanocapsule sizing on a nanocapsule uptake in human keratinocytes

[0153] The effect of nanocapsule sizing on intracellular trafficking in immortalized HacaT human keratinocyte cultures (HacaT's) was investigated in this example. In this

TABLE 1B

Effective of process parameters on particle functionality

Nano capsule Design	Formula Name	charge neutralization by condensor	Surfactant	Biocompatible Oil	Oil Phase Volume (%, 4.5 ml basis)	Emulsify by sonication	Atomize Diameter (μm)	Receiving bath Osmolality (mOs)
1	q.co.2	+	Cetyl OH	Castor oil/Etoh	4	+	250	220
2	q.co	—	Cetyl OH	Castor oil/Etoh	4	+	250	220
3	o.35	+	TM-diol	DMSO	4	+	1.4	220
4	ea0.2	+	TM-diol	DMSO	4	—	—	220
5	ea0.1	—	TM-diol	DMSO	4	—	—	220
6	ed0.2	+	TM-diol	DMSO	0.05	—	250	220
7	ed0a.12.di	+	TM-diol	DMSO	0.05	—	250	0

Nanocapsule Design	Formula name	Nanocapsule diameter (nm)* n = 20	Encapsulation yield (%, mean ± SE)	Transduction Efficiency, (5 days, rat fibroblasts)
1	q.co.2	20 ± 3, rods	48.6 ± 11	87 ± 7%
2	q.co	12 ± 0.7, irregular	48.6 ± 2	71 ± 28%
3	o.35	17 ± 1.2, spheres	82.3 ± 7 (4)	86 ± 2%
4	ea0.2	24 ± 2, s/r	32 ± 10	72 ± 2%
5	ea0.1	36 ± 3, irregular	57 ± 2	85 ± 1%
6	ed0.2	39 ± 3, r/e	39 ± 5	96%
7	ed0a12.di	39 ± 3, ellipse	69 ± 2	100%

*Nanocapsule diameter is reported as average of the minor and major particle axis using digital image analysis, while nanocapsule morphology is reported as irregular, rods (r), ellipse (e) or spheres (s).

series of formulae, thee micellar dispersion were sheared by syringes of different orifice diameter. The coating weight was also lowered from 1:1 DNA:Polymer (w/w) to 1:40 to shorten the dissolution profile from 5 to 3 days. In these experiments, nanocapsule formulae were compared to standard polyplexes of DNA and PEI, and lipoplexed plasmid DNA. Table 2 summarizes the experimental design and results:

TABLE 2

Effect of particle size on nanocapsule functionality for gene transfer

Formula Name	Particle Size (mean, nm; morphology)	4 hr. colocalization with caveolin-1*	4 hr. colocalization with cathrin	10 hr. colocalization with lysosomes	Transduction Efficiency. (5 days, human keratinocytes)
o.22 (64)	47 ± 3, rods	0	++	+	16 ± 13
o.27 (57)	21 ± 2, rods	+	+	ND	81 ± 8
o.35 (85)	17 ± 1.2, spheres	+++	0	0	78 ± 9
pei-pDNA	67 ± 4, spheres, irreg	0	+++	+++	40 ± 15
Lipoplex pDNA	48 ± 2 200 nm aggregates	+	+	+++	41 ± 27

Key: 0 = no change from unstimulated condition,
+ greater than 25% increase,
++ greater than 50% increase,
+++ greater than 75% increase in number of cells stimulated.
ND = not determined.

[0154] It was observed that compared to the unstimulated state, nanocapsules increased cellular pinocytotic activity compared to standard formulations, and smaller nanocapsules shifted pinocytotic activity to caveolae from clathrin-coated pits (Table 2: Formula O vs. pei-dna and lipoplex pDNA). It was further observed that nanocapsules avoided lysosome co-localization at 10 hours post-addition with smaller nanocapsules being particularly effective (see Table 2: Formula vs. pei-dna and lipoplex pDNA). These results are illustrated further in **FIG. 2**. This improvement is further emphasized by comparison with published uptake studies for HacaT keratinocytes. Compared to primary keratinocytes, uptake of naked DNA oligonucleotides (20 μm) were very poor in HacaT's and showed accumulation of oligonucleotides in punctate vesicles consistent lysosomes at 2 hours. Using hydrophillic dispersed atomized nanocapsules of the inventive method, complete avoidance of lysosomes at 10 hours post-addition was demonstrated. These results indicate that products of the inventive process will have increased and prolonged effectiveness.

Example 3—Effect of nanoparticle delivery on DNA and reagent-induced cytoxicity

[0155] To test whether soluble exogenous DNA released from liposomes or dendrimers induces apoptosis, Rt-1's were treated with loaded/unloaded liposome complexes, dendrimer complexes, nanoparticles and 1 μg/ml etoposide, a DNA intercalating agent as a positive control. Cultures were treated with standard formulas for 3 hours then assayed for gene product expression 30 hours later. Cultures were treated with nanocapsules for 4 days to ensure full DNA release during the experiment. Controls included as a positive control for apoptotic cell death, 1 μg/ml etoposide, a DNA intercalating agent was applied to cultures overnight before experiment termination. Other controls included standard PEI-DNA complexes, empty nanocapsules and nanocapsules containing empty vector plasmid DNA. Hydrophillic nanoparticles were produced for this experiment as described earlier using a 35-gage syringe.

[0156] One of the later steps in apoptosis is DNA fragmentation mediated by activation of endonucleases during the apoptic program. Therefore, DNA fragmentation was assayed by end-labeling of fragments using an exogenous enzyme and a substituted nucleotide (TUNEL: tdt-mediated uridine nucleotide and labeling. Results are expressed as a Fragmentation Index, or the percent of cells in the total culture exhibiting BRDU end-labeled DNA. Cultures were run in duplicate. The experimental design and results are summarized in Table 3:

TABLE 3

Effect of nanocapsule coating weight on nonspecific reagent and plasmid DNA-associated cytoxicity.

	Formula			
	κ.35	ζ	o(Omicron)	b.35
Particle Design:				
DNA Condensing Agent	Denatured h. keratinocyte nuclear protein	100 Kd MW Polylsine	27 kD PEI	27 kD PEI
Coating Ratio (DNA/polymer)	0.1	0.25	0.25	0.01
Performance:				
dose: (30 hrs for Std. Formulas, 100 hrs for nanocapsules)	4.6	4.1	4	5
Cytotoxicity: (Fragmentation Index, %) cytotoxicity controls: (1 μg etoposide (8 hr): 25 ± 10%) (Pei-DNA polyplexes (100 hr): 24 ± 7%) (Empty vector nanocapsules: 1.25 ± 1.25%) (Empty vector nanocapsules: 0.9 ± 0.7%)	ND	0.26 ± 0.15	2 ± 0.7	1.9 ± 0.6
Transduction Efficiency: (% cells) 120 hrs, dose as listed)	31 ± 2	ND	85 ± 7	32 ± 3
Formula Characteristics:				
Nucleic: Acid Incorporation: (%)	55 ± 10	27 ± 7	54 ± 5	65 ± 4
Cumulative Release: (%, 48 hr)	70	75 ± 8	83 ± 12	ND
Particle Size (mean ± SE, nm)	26 ± 2	22 ± 2	20 ± 1	35 ± 2
Agglomerates (as dispensed)	few	50% 80 ± 6	200 nm	200 nm

	Formula			
	Y.35	Lipoplex GP	Lipoplex L+	Polyplex
Particle Design:				
DNA Condensing Agent	27 kD PEI	cationic lipid	cationic lipid	dendrimer
Coating Ratio (DNA/polymer)	0.0025			
Performance:				
dose: (30 hrs for Std. Formulas, 100 hrs for nanocapsules)	5	1 μg 500 ng 0 ng	500 ng 250 ng 0 ng	2 μg 1 μg 0 μg
Cytotoxicity: (Fragmentation Index, %)	9 ±8	27 ± 8	9.3 ± 0.2	6.63 ± 1.4
cytotoxicity controls: (1 μg etoposide (8 hr): 25 ± 10%) (Pei-DNA polyplexes (100 hr): 24 ± 7%) (Empty vector nanocapsules:		6 ± 3 4 ± 2.5	12.8 ± 1.5 7.8 ± 0.1	5.7 ± 1.8 3.1 ± 0.3

TABLE 3-continued

Effect of nanocapsule coating weight on nonspecific reagent and plasmid DNA-associated cytoxicity.

1.25 ± 1.25%) (Empty vector nanocapsules: 0.9 ± 0.7%) Transduction Efficiency: (% cells) 120 hrs, dose as listed) Formula Characteristics:	24	± 4	17 ± 2	dead	dead
Nucleic: Acid Incorporation: (%)	667	±0.2	ND	ND	ND
Cumulative Release: (%, 48 hr)	ND		ND	ND	ND
Particle Size (mean ± SE, nm)	57	± 5	48 ± 2	ND	22.4 ± 2
Agglomerates (as dispensed)	g.t.50% 300 nm		300 nm		25% 300 nm hard-fused

[0157]

TABLE 3B

Dose response of nanoencapsulated pDNA

Formula	Dose (100 hr.)	GFP/Actin Production (density ratio, %)
K.35	9 μg	94.8
K.35	4.5 μg	83.5
K.35	1.5 μg	83.3
Lipoplex GP	o.5 μg	94.9

[0158] It was observed that use of controlled-release nanocapsules reduced the fraction of apoptotic cells in fibroblast cultures 3 to 100 fold. Conventional reagents without DNA showed a 4-fold increase in FI over empty nanoparticles, but increased another 50-100% without additional reagents in the presence of additional DNA. Decreasing the coating weight from 1:40 to 1:400 resulted in an increase in average nanocapsule diameter from 20 to 57 nm and the appearance of regions of apoptotic induction in cultures (Table 3: F omicron vs. F upsilon 35). Decreasing the coating weight from 1:40 to an intermediate 1:100 reduced transduction efficiency without increasing particle size and the appearance of cytotoxicity. These findings indicate that nanocapsule design plays a role in maintaining nanocapsule integrity and that size effects and dissolution profiles can contribute to observed cytotoxicity and functionality. We concluded that application of nanocapsule formulations increased dosing to useful efficiency levels without induction of an apoptotic program.

[0159] Table 3B exemplifies this improvement with a dose response of Formula K.35 measured in fibroblast lysates. GFP production was measured in fibroblast lysates after 4 days of treatment with increasing doses of nanocapsules. A 9.5 μg dose of nanocapsules equaled the production of a liposomal formulation without any evidence of cytotoxicity.

Example 4—Nanocapsule delivery of macromolecules to porcine tissue across keratinized barrier epithelia bv transdermal and subcutaneous means

[0160] The utility of nanocapsules for nonviral nucleic acid delivery to tissue in a pig biopsy organ culture system was investigated. 6 and 8 mm circular biopsies were collected under sterile conditions from sedated research animals and cultured on meshes in partial contact with media containing 20% Fetal Calf Serum. Biopsies were either injected with 90 μl (6.3 μg) or treated topically with 3×30 μl aliquots. Biopsies were snapfrozen 7 days later and sectioned/homogenized for β-galactosidase production measurement. Formulation information and results from this experiment are summarized in Table 4:

TABLE 4:

Table 4: Functionality of dispersed atomized nanocapsules for macromolecule delivery across keratinized barrier membranes.

	Formula N	Formula O
Exp. Modification (from Formula Q)	coating wt. is 2.5x Polymer MW is 1x	coating wt. is 2.5x Polymer MW is 4x
Formula Characteristics:		
Nucleic Acid Incorporation (%)	70.00	70.50
Cumulative Release (%, 169 hr 2.5 μg sample	83	83. ± 1.5
Low MW DNA in postdigested Electrophoresis Samples	0	0
Supercoil retention (237 hr release, initial = 69.7% sc/releaxed)	100%	100%
Particle Size (mean, SE, major species)	18.2 ± 0.2 nm	ND
Particle Description	spherical	
Secondary structure:	20% 100 nm flocs	

TABLE 4:-continued

Table 4: Functionality of dispersed atomized nanocapsules for macromolecule delivery across keratinized barrier membranes.

Performance:		
Transduced Protein Production (pixel units, % of neg control, 100 μg total protein, normalized by protein)	312 ± 74 (topical) 142 (s.c.)	
Reporter (gene Product Distribution (6.3 μg dose, 6 mm (N), 8 mm (O) porcine biopsy, 1 wk)	100%	100%
keratinocytes (% cells), n = 2 fields/200 cells, neg cntrl: 6% endothelial cells, (% vwf-+area)	73 ± 20 (pap)	13.8 ± 0.5 (pap)
papillary and/or reticular, n = 2–4 fields, neg cntrl: 1.07 ± 0.72	32 ± 15 (ret)	8 ± 2 (ret)
dermis (% area); negative cntrl: 0.24 ± 0.03, n = 4/20x fields	2.74 ± 0.96*	1.77 ± 0.49*

*= $p < 0.05$

[0161] Western blotting of radiated tissue lysates showed a 3-fold increase in β-galactosidase in duplicate biopsies treated topically with Formula N over an identically cultured 6mm biopsy treated with saline. Only a 2-fold increase was measured in a 8 mm biopsy treated topically with formula 0 nanoparticles (see **FIG. 4B**). Formula O was produced with a higher molecular weight analog of the N polymer suggesting a difference in particle morphology, a dose effect or differing in situ release profiles between the two formulations related to this difference. To identify initial cell type-specific differences in nanocapsule delivery effectiveness, tissue sections were analyzed for β-galactosidase expression in double-label experiments using antibodies to cell-specific epitopes (see **FIG. 4B**). Digital image analysis of these sections indicated that radiated keratinocytes and endothelial cells are readily transduced in organ culture 7 days after treatment with a 10 day releasing formula. Specific quantitation of fibroblastic cells was not possible without inclusion of a cell-specific marker, however, an 11-fold increase in area of expression was measured in N biopsy dermis (see **FIG. 4B**). Interestingly, for both the formulae N and O topically-treated biopsies examined, the area percentage of blood vessels transduced decreased about 50% in nearby fields between 100 μm and 300 μm of depth (Table 4: papillary vs. reticular endothelial cells). These data suggest that nanocapsules are penetrating the epidermis to enter the dermis.

Example 5—Incorporation of inventive nanocapsules into a solid dosage form for additional utility in physical targeting

[0162] Nanocapsules containing a nuclear GFP transgene or empty vector were incorporated into a suture coating by vortexing the following components: i) 50 μg of nanocapsules containing plasmid DNA, ii) 200 μg of bovine mucin, and iii) 75 μg of sucrose (60% w/w) in a 1000 μl volume. Sutures were aseptically coated by drawing sutures 5× through punctured microcentrifuge tubes. Coating functionality for gene transfer was tested by applying sutures in cultured porcine skin biopsies. Biopsies were cultured on a mesh such that the biopsy bottom was in contact with cell culture media. Biopsies were treated for 7 days, then snap-frozen and sectioned for immunofluorescence microscopy to assess nanocapsule penetration and transgene delivery.

[0163] Nanocapsule penetration was detected by streptavidin-biotin immunocomplexes directed at sheep IgG. Nanocapsule coatings are spiked with ovine IgG to enable this detection strategy. **FIG. 5A** shows distribution of sheep IgG signal throughout porcine dermal tissue with accumulation on capillaries. In **FIG. 5**A', primary antibody is omitted during slide processing to determine level of background fluorescence. A suture is visible in this view. Sutures were identifiable as smooth objects without positive nuclear counterstain. GFP expression was confirmed using a polyclonal GFP antibody to obviate the effect of nonspecific tissue green fluorescence. **FIG. 5B** shows GFP expression throughout the suture-treated dermis using a GFP polyclonal antibody. A suture was visible 750 microns away. **FIG. 5C** shows the lack of GFP expression in a biopsy treated with empty vector coating. This example demonstrates the usefulness of nanocapsules for use in physically targeted macromolecule delivery.

Example 6—Utility of nanocapsules for local targeting by design of nanocapsule coating

[0164] Fibroblast targeting

[0165] GFP nanocapsules were prepared by dispersion atomization as described in Example 1. Polyvinylpyrylodone (PVP, MW 10,000) was used as the coating basis. A coating weight ratio of 1:40 was used and rod-shaped nanocapsules of 23±2 nm were produced. 1 μg of PVP nanocapsules were applied to both human dermal fibroblasts (HDF) and HacaT keratinocyte cultures for 4 hours then fixed for detection for nanocapsule uptake by streptavidin-bioting immunocomplexes to sheep IgG. Nanocapsule coatings are spiked with ovine IgG to enable this detection strategy. **FIG. 6** illustrates positive nuclear localization of PVP nanocapsules in HDF's and negative colocalization of PVP nanocapsules in keratinocytes (**FIG. 6**: **6***a* vs. **6***b*). Views of untreated cultures are included for comparison (**6***a*', **6***b*'). Cultures were also treated with 5 μg of PVP nanocapsules for 5 days then tested for GFP transgene production. Consistent with uptake studies results, only the fibroblast cultures showed production of GFP transgene (**FIG. 6**: **6***a*" vs. **6***b*").

[0166] Tumor-targeting

[0167] GFP nanocapsules were prepared by dispersion atomization as described in example 1. Tenascin (TN, MW 200,000) was used as the coating basis. A coating weight ratio of 1:20 was used and spherical nanocapsules of 19±0.9 nm were produced. 500 ng of TN nanocapsules were applied topically in successive small aliquots to pig biopsies maintained in organ culture. Biopsies were rinsed in media after 3 minutes of topical application and culture media was changed to preclude any delivery other than topical.

[0168] To simulate tumor nests of epithelial-derived origin, biopsies had been seeded 12 hours previously with 50,000 human squamous carcinoma cells. 7 days later biopsies were snapfrozen and sectioned for immunological detection of GFP production. In **FIG. 6**B, view "a" shows

intense GFP fluorescence in the tumor center, view "b" confirms this GFP expression with polyclonal antibodies to GFP, view "c" shows cell positioning in the section using a counterstain for cell nuclei and view "d" shows the level of background fluorescence by omission of GFP antibodies. Tumor origin was confirmed by positive detection with antibody to keratin 10/1, an epithelial marker. Comparison of view "b" and view "c" indicates that GFP expression is limited to cells within the tumor. As already demonstrated in example 5, expression throughout a tissue is also feasible and can modulated by coating design. This example demonstrates that nanocapsule delivery can be productively targeted.

[0169] Cell-specific delivery for enhanced drug therapeutic window

[0170] Nanocapsules were prepared as described in Example 1 to encapsulate cisplatin, a hydrophobic molecule and a common cancer chemotherapeutic with serious side effects. A coating weight ratio of 1:100 was used and irregular nanocapsules of 29±3 nm were produced. Targeting efficacy was demonstrated by changes in the dose response for cell growth inhibition in fibroblast vs. squamous cell carcinoma cultures. Cells were seeded overnight into 96 well plates, treated for 18 hours with increasing amounts of encapsulated or unencapsulated drug, then assessed for cell growth inhibition using an MTT assay 48 hours later for total growth time of 72 hours. Results are illustrated in **FIG. 6C**. The data shows that tenascin nanocapsules protected nontarget cells from cell death (zero death) at drug levels that killed using unencapsulated drug (**FIG. 6**Aa: open vs. closed circles). In carcinoma cultures, TN nanocapsules productively decreased the inhibition concentration (IC50) an estimated 300% from 525 to 160 μg/ml. Example 6 demonstrates the usefulness of nanocapsules for use in coating-targeted macromolecule delivery.

Example 7—Utility of nanoencapsulation for improved cellular uptake of other species used as pharmaceutical, nutraceutical, research or cosmetic agents

[0171] Nanocapsules containing either 500 kD Fitc-labelled dextran, 20 mer Fitc-labelled mer O-methylated RNA oligonucleotide and 16 mer phosphodiester DNA oligonucleotide were prepared as described in Example 1. A 1:40 coating weight ratio was used and 1 MM kD hyaluronan was used a coating basis. PEI was used to condense the phosphodiester DNA oligonucleotide, but no PEI was included in the dextran or RNA oligonucleotide formulas. Nanocapsule functionality for drug delivery was tested by evaluating changes in relative pinocytotic activity and cellular uptake in 35 mm cultures of human dermal fibroblast. Nanocapsule formulas were compared to naked species or species formulated as complexes. Quantitative results are summarized in Table 7.

TABLE 6

Nanoencapsulation improves cellular uptake of other species used as pharmaceutical, nutraceutical, research or cosmetic agents. At 18 hours post-addition, lysosomes are only evident in conventionally formulated species.

			4.5 hours post-addition			18 hours post-addition		
Bioactive Component	Formulation	Particle size (mean, SE, nm, morphology)	Increase in cellular uptake activity, (% cells above baseline, caveolin-l/clathrin)	dose	Nuclear Uptake Efficiency (% cells, fibroblast)	Bioactive component Colocalization with lysosomes, (% cells, human fibroblasts)		Detection persistence (% cell, human fibroblast)
500 kd flic-dextran	nanocapsule	22 ± 2, s/r	89/20	25 μg*	95 ± 2	2 ± 2	5 μg	88 ± 11
	naked, Fitclabelled	—	75/18	100 μg	10	100 ± 10	100 μg	61 ± 20
20 mer o-methylated RNA oligo	nanocapsule	13 ± 0.7, r	78/90	2 μg	74 ± 5	0 ± 0	5 μg	80 ± 6
	naked, Fitclabelled	—	—/73	5 μg	14 ± 7	—	—	
	PEI/Fitclabelled	236 ± 26, r	—/—	—	—	100 ± 0	5 μg	94 ± 10
16 mer PO DNA oligo	nanocapsule	17 ± 1, r	70/94	1 μg	34 ± 25	0 ± 0	5 μg	91 ± 8
	PEI/Fitclabelled	67 ± 4, s/r	72% lysosomes	2 μg	95 ± 2	80 ± 7	5 μg	66
Nominal n		20 particles	70 cells		140 cells	50 cells		50 cells

*Dose was estimated for encapsulation dextran assuming 100% encapsulation.
s = sphere
r = rod

[0172] Table 7 shows that average diameters for all nanocapsules were below 50 nm by AFM. PEI complexes of DNA oligonucleotides were measured at 67 nm and PEI complexes of uncharged RNA O-methyl oligonucleotides were measured at 236 nm. As discussed in Example 2 using keratinocyte cultures and plasmid DNA, nanocapsules stimulate pinocytotic activity as indicated by increased signal levels of clathrin and caveolin-1. In the 500 kD dextran case, pinocytotic activity shifts productively towards caveolae with nanoencapsulation (Table 7, 500 kD Dextran). At 4.5 hours post-addition, nuclear uptake is enhanced for encapsulated dextran and RNA relative to naked species. For the nanocapsules of DNA oligonucleotides, cellular uptake is decreased relative to complexed oligonucelotide, however, a majority of that DNA oligonucleotides is already nonproductively sequestered in lyso-

somes by that 4.5 hours (Table 7). At 18 hours post-addition, nanocapsules species show continued exclusion from lysosomes, while naked species show high levels of sequestration. These results are illustrated in **FIG. 7A and 7B**. Views "a" and "b" show Fitc detection in cultures at 18 hours. That distribution is exclusively nuclear for the nanoencapsules of RNA oligonucelotides (**FIG. 7**B: a vs. a'). Punctate inclusion are visible in the cultures treated with the complexed RNA oligonucleotides that co-localize with an immunological marker for lysosomes (**FIG. 7**A: a vs. a'). Particle sizing results from AFM microscopy are included to demonstrate dramatic difference in sizing following encapsulation. (**FIG. 7**A, **7**B:b vs.b, b'). Formulas encapsulating lower molecular weight dextrans and unstabilized RNA were also prepared with analagous uptake, nanocapsule size and yield to demonstrate that encapsulation can provide not only a targeting function but aid in stabilizing molecules sensitive to chemical or enzymatic degradation. These examples demonstrates the usefulness of nanocapsules **36** for use in delivery of a broad range of macromolecules.

[**0173**] Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 5

<210> SEQ ID NO 1
<211> LENGTH: 6232
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Supplied by Invitrogen of Carlsbad, California

<400> SEQUENCE: 1

gtaccgaatt caagcttcgt gaggctccgg tgcccgtcag tgggcagagc gcacatcgcc 60

cacagtcccc gagaagttgg ggggaggggt cggcaattga accggtgcct agagaaggtg 120

gcgcggggta aactgggaaa gtgatgtcgt gtactggctc cgccttttc ccgagggtgg 180

gggagaaccg tatataagtg cagtagtcgc cgtgaacgtt ctttttcgca acgggtttgc 240

cgccagaaca caggtaagtg ccgtgtgtgg ttcccgcggg cctggcctct ttacgggtta 300

tggcccttgc gtgccttgaa ttacttccac ctggctccag tacgtgattc ttgatcccga 360

gctggagcca ggggcgggcc ttgcgcttta ggagcccctt cgcctcgtgc ttgagttgag 420

gcctggcctg ggcgctgggg ccgccgcgtg cgaatctggt ggcaccttcg cgcctgtctc 480

gctgctttcg ataagtctct agccatttaa aatttttgat gacctgctgc gacgcttttt 540

ttctggcaag atagtcttgt aaatgcgggc caggatctgc acactggtat ttcggttttt 600

gggcccgcgg ccggcgacgg ggcccgtgcg tcccagcgca catgttcggc gaggcggggc 660

ctgcgagcgc ggccaccgag aatcggacgg gggtagtctc aagctggccg gcctgctctg 720

gtgcctggcc tcgcgccgcc gtgtatcgcc ccgccctggg cggcaaggct ggcccggtcg 780

gcaccagttg cgtgagcgga aagatggccg cttcccggcc ctgctccagg gggctcaaaa 840

tggaggacgc ggcgctcggg agagcgggcg ggtgagtcac ccacacaaag gaaaagggcc 900

tttccgtcct cagccgtcgc ttcatgtgac tccacggagt accgggcgcc gtccaggcac 960

ctcgattagt tctggagctt ttggagtacg tcgtctttag gttgggggga ggggttttat 1020

gcgatggagt ttccccacac tgagtgggtg gagactgaag ttaggccagc ttggcacttg 1080

atgtaattct ccttggaatt tggccttttt gagtttggat cttggttcat tctcaagcct 1140

cagacagtgg ttcaaagttt ttttcttcca tttcaggtgt cgtgaacacg tggccaccat 1200

ggcccaggtg cagctgcaga tggctagcaa aggagaagaa cttttcactg gagttgtccc 1260

aattcttgtt gaattagatg gtgatgttaa tgggcacaaa ttttctgtca gtggagaggg 1320

tgaaggtgat gctacatacg gaaagcttac ccttaaattt atttgcacta ctggaaaact 1380

-continued

acctgttcca tggccaacac ttgtcactac tttctcttat ggtgttcaat gcttttcccg 1440

ttatccggat catatgaaac ggcatgactt tttcaagagt gccatgcccg aaggttatgt 1500

acaggaacgc actatatctt tcaaagatga cgggaactac aagacgcgtg ctgaagtcaa 1560

gtttgaaggt gataccctg ttaatcgtat cgagttaaaa ggtattgatt ttaaagaaga 1620

tggaaacatt ctcggacaca aactcgagta caactataac tcacacaatg tatacatcac 1680

ggcagacaaa caaaagaatg gaatcaaagc taacttcaaa attcgccaca acattgaaga 1740

tggatccgtt caactagcag accattatca acaaaatact ccaattggcg atggccctgt 1800

ccttttacca gacaaccatt acctgtcgac acaatctgcc ctttcgaaag atcccaacga 1860

aaagcgtgac cacatggtcc ttcttgagtt tgtaactgct gctgggatta cacatggcat 1920

ggatgagctc tacaaagcgg ccgcagatcc aaaaaagaag agaaaggtag atccaaaaaa 1980

gaagagaaag gtagatccaa aaaagaagag aaaggtagat acggccgcag aacaaaaact 2040

catctcagaa gaggatctga atggggccgc atagtctaga agctcgctga tcagcctcga 2100

ctgtgccttc tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc 2160

tggaaggtgc cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc 2220

tgagtaggtg tcattctatt ctgggggggtg gggtggggca ggacagcaag ggggaggatt 2280

gggaagacaa tagcaggcat gctggggatg gcccgggctc tatggcttct gaggcggaaa 2340

gaaccagctg gggctctagg gggtatcccc acgcgccctg tagcggcgca ttaagcgcgg 2400

cgggtgtggt ggttacgcgc agcgtgaccg ctacacttgc cagcgcccta gcgcccgctc 2460

ctttcgcttt cttcccttcc tttctcgcca cgttcgccgg ctttccccgt caagctctaa 2520

atcggggcat ccctttaggg ttccgattta gtgctttacg gcacctcgac cccaaaaaac 2580

ttgattaggg tgatggttca cgtagtgggc catcgccctg atagacggtt tttcgccctt 2640

tgacgttgga gtccacgttc tttaatagtg gactcttgtt ccaaactgga acaacactca 2700

accctatctc ggtctattct tttgatttat aagggatttt ggggatttcg gcctattggt 2760

taaaaaatga gctgatttaa caaaaattta acgcgaatta attctgtgga atgtgtgtca 2820

gttagggtgt ggaaagtccc caggctcccc aggcaggcag aagtatgcaa agcatgcatc 2880

tcaattagtc agcaaccagg tgtggaaagt ccccaggctc cccagcaggc agaagtatgc 2940

aaagcatgca tctcaattag tcagcaacca tagtcccgcc cctaactccg cccatcccgc 3000

ccctaactcc gcccagttcc gcccattctc cgcccctagg ctgactaatt ttttttattt 3060

atgcagaggc cgaggccgcc tctgcctctg agctattcca gaagtagtga ggaggctttt 3120

ttggaggcct aggcttttgc aaaaagctcc cgggaggtcc acaatgattg aacaagatgg 3180

attgcacgca ggttctccgg ccgcttgggt ggagaggcta ttcggctatg actgggcaca 3240

acagacaatc ggctgctctg atgccgccgt gttccggctg tcagcgcagg ggcgcccggt 3300

tctttttgtc aagaccgacc tgtccggtgc cctgaatgaa ctccaggacg aggcagcgcg 3360

gctatcgtgg ctggccacga cgggcgttcc ttgcgcagct gtgctcgacg ttgtcactga 3420

agcgggaagg gactggctgc tattgggcga agtgccgggg caggatctcc tgtcatctca 3480

ccttgctcct gccgagaaag tatccatcat ggctgatgca atgcggcggc tgcatacgct 3540

tgatccggct acctgcccat tcgaccacca agcgaaacat cgcatcgagc gagcacgtac 3600

tcggatggaa gccggtcttg tcgatcagga tgatctggac gaagagcatc aggggctcgc 3660

-continued

gccagccgaa ctgttcgcca ggctcaaggc gcgtatgccc gacggcgagg atctcgtcgt 3720

gactcatggc gatgcctgct tgccgaatat catggtggaa aatggccgct tttctggatt 3780

catcgactgt ggccggctgg gtgtggcgga ccgctatcag gacatagcgt tggctacccg 3840

tgatattgct gaagagcttg gcggcgaatg ggctgaccgc ttcctcgtgc tttacggtat 3900

cgccgctccc gattcgcagc gcatcgcctt ctatcgcctt cttgacgagt tcttctgagc 3960

gggactctgg ggttcgaaat gaccgaccaa gcgacgccca acctgccatc acgagatttc 4020

gattccaccg ccgccttcta tgaaaggttg ggcttcggaa tcgttttccg ggacgccggc 4080

tggatgatcc tccagcgcgg ggatctcatg ctggagttct tcgcccaccc caacttgttt 4140

attgcagctt ataatggtta caaataaagc aatagcatca caaatttcac aaataaagca 4200

ttttttttcac tgcattctag ttgtggtttg tccaaactca tcaatgtatc ttatcatgtc 4260

tgtataccgg atctttccgc ttcctcgctc actgactcgc tgcgctcggt cgttcggctg 4320

cggcgagcgg tatcagctca ctcaaaggcg gtaatacggt tatccacaga atcaggggat 4380

aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc 4440

gcgttgctgg cgtttttcca taggctccgc cccctgacg agcatcacaa aaatcgacgc 4500

tcaagtcaga ggtggcgaaa cccgacagga ctataaagat accaggcgtt tccccctgga 4560

agctccctcg tgcgctctcc tgttccgacc ctgccgctta ccggatacct gtccgccttt 4620

ctcccttcgg gaagcgtggc gctttctcaa tgctcacgct gtaggtatct cagttcggtg 4680

taggtcgttc gctccaagct gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc 4740

gccttatccg gtaactatcg tcttgagtcc aacccggtaa gacacgactt atcgccactg 4800

gcagcagcca ctggtaacag gattagcaga gcgaggtatg taggcggtgc tacagagttc 4860

ttgaagtggt ggcctaacta cggctacact agaaggacag tatttggtat ctgcgctctg 4920

ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa acaaaccacc 4980

gctggtagcg gtggtttttt tgtttgcaag cagcagatta cgcgcagaaa aaaaggatct 5040

caagaagatc ctttgatctt ttctacgggg tctgacgctc agtggaacga aaactcacgt 5100

taagggattt tggtcatgag attatcaaaa aggatcttca cctagatcct tttaaattaa 5160

aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa cttggtctga cagttaccaa 5220

tgcttaatca gtgaggcacc tatctcagcg atctgtctat ttcgttcatc catagttgcc 5280

tgactccccg tcgtgtagat aactacgata cgggagggct taccatctgg ccccagtgct 5340

gcaatgatac cgcgagaccc acgctcaccg gctccagatt tatcagcaat aaaccagcca 5400

gccggaaggg ccgagcgcag aagtggtcct gcaactttat ccgcctccat ccagtctatt 5460

aattgttgcc gggaagctag agtaagtagt tcgccagtta atagtttgcg caacgttgtt 5520

gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg gtatggcttc attcagctcc 5580

ggttcccaac gatcaaggcg agttacatga tcccccatgt tgtgcaaaaa agcggttagc 5640

tccttcggtc ctccgatcgt tgtcagaagt aagttggccg cagtgttatc actcatggtt 5700

atggcagcac tgcataattc tcttactgtc atgccatccg taagatgctt ttctgtgact 5760

ggtgagtact caaccaagtc attctgagaa tagtgtatgc ggcgaccgag ttgctcttgc 5820

ccggcgtcaa tacgggataa taccgcgcca catagcagaa ctttaaaagt gctcatcatt 5880

ggaaaacgtt cttcggggcg aaaactctca aggatcttac cgctgttgag atccagttcg 5940

-continued

atgtaaccca ctcgtgcacc caactgatct tcagcatctt ttactttcac cagcgtttct 6000

gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc gacacggaaa 6060

tgttgaatac tcatactctt cctttttcaa tattattgaa gcatttatca gggttattgt 6120

ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaatagg ggttccgcgc 6180

acatttcccc gaaaagtgcc acctgacgtc agatcgacgg atcgggagat cg 6232

<210> SEQ ID NO 2
<211> LENGTH: 2200
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

Met Gly Ala Met Thr Gln Leu Leu Ala Gly Val Phe Leu Ala Phe Leu
1 5 10 15

Ala Leu Ala Thr Glu Gly Gly Val Leu Lys Lys Val Ile Arg His Lys
20 25 30

Arg Gln Ser Gly Val Asn Ala Thr Leu Pro Glu Glu Asn Gln Pro Val
35 40 45

Val Phe Asn His Val Tyr Asn Ile Lys Leu Pro Val Gly Ser Gln Cys
50 55 60

Ser Val Asp Leu Glu Ser Ala Ser Gly Glu Lys Asp Leu Ala Pro Pro
65 70 75 80

Ser Glu Pro Ser Glu Ser Phe Gln Glu His Thr Val Asp Gly Glu Asn
85 90 95

Gln Ile Val Phe Thr His Arg Ile Asn Ile Pro Arg Arg Ala Cys Gly
100 105 110

Cys Ala Ala Ala Pro Asp Val Lys Glu Leu Leu Ser Arg Leu Glu Glu
115 120 125

Leu Glu Asn Leu Val Ser Ser Leu Arg Glu Gln Cys Thr Ala Gly Ala
130 135 140

Gly Cys Cys Leu Gln Pro Ala Thr Gly Arg Leu Asp Thr Arg Pro Phe
145 150 155 160

Cys Ser Gly Arg Gly Asn Phe Ser Thr Glu Gly Cys Gly Cys Val Cys
165 170 175

Glu Pro Gly Trp Lys Gly Pro Asn Cys Ser Glu Pro Glu Cys Pro Gly
180 185 190

Asn Cys His Leu Arg Gly Arg Cys Ile Asp Gly Gln Cys Ile Cys Asp
195 200 205

Asp Gly Phe Thr Gly Glu Asp Cys Ser Gln Leu Ala Cys Pro Ser Asp
210 215 220

Cys Asn Asp Gln Gly Lys Cys Val Asn Gly Val Cys Ile Cys Phe Glu
225 230 235 240

Gly Tyr Ala Gly Ala Asp Cys Ser Arg Glu Ile Cys Pro Val Pro Cys
245 250 255

Ser Glu Glu His Gly Thr Cys Val Asp Gly Leu Cys Val Cys His Asp
260 265 270

Gly Phe Ala Gly Asp Asp Cys Asn Lys Pro Leu Cys Leu Asn Asn Cys
275 280 285

Tyr Asn Arg Gly Arg Cys Val Glu Asn Glu Cys Val Cys Asp Glu Gly
290 295 300

-continued

```
Phe Thr Gly Glu Asp Cys Ser Glu Leu Ile Cys Pro Asn Asp Cys Phe
305                 310                 315                 320

Asp Arg Gly Arg Cys Ile Asn Gly Thr Cys Tyr Cys Glu Glu Gly Phe
                325                 330                 335

Thr Gly Glu Asp Cys Gly Lys Pro Thr Cys Pro His Ala Cys His Thr
            340                 345                 350

Gln Gly Arg Cys Glu Glu Gly Gln Cys Val Cys Asp Glu Gly Phe Ala
        355                 360                 365

Gly Leu Asp Cys Ser Glu Lys Arg Cys Pro Ala Asp Cys His Asn Arg
    370                 375                 380

Gly Arg Cys Val Asp Gly Arg Cys Glu Cys Asp Asp Gly Phe Thr Gly
385                 390                 395                 400

Ala Asp Cys Gly Glu Leu Lys Cys Pro Asn Gly Cys Ser Gly His Gly
                405                 410                 415

Arg Cys Val Asn Gly Gln Cys Val Cys Asp Glu Gly Tyr Thr Gly Glu
            420                 425                 430

Asp Cys Ser Gln Leu Arg Cys Pro Asn Asp Cys His Ser Arg Gly Arg
        435                 440                 445

Cys Val Glu Gly Lys Cys Val Cys Glu Gln Gly Phe Lys Gly Tyr Asp
    450                 455                 460

Cys Ser Asp Met Ser Cys Pro Asn Asp Cys His Gln His Gly Arg Cys
465                 470                 475                 480

Val Asn Gly Met Cys Val Cys Asp Asp Gly Tyr Thr Gly Glu Asp Cys
                485                 490                 495

Arg Asp Arg Gln Cys Pro Arg Asp Cys Ser Asn Arg Gly Leu Cys Val
            500                 505                 510

Asp Gly Gln Cys Val Cys Glu Asp Gly Phe Thr Gly Pro Asp Cys Ala
        515                 520                 525

Glu Leu Ser Cys Pro Asn Asp Cys His Gly Gln Gly Arg Cys Val Asn
    530                 535                 540

Gly Gln Cys Val Cys His Glu Gly Phe Met Gly Lys Asp Cys Lys Glu
545                 550                 555                 560

Gln Arg Cys Pro Ser Asp Cys His Gly Gln Gly Arg Cys Val Asp Gly
                565                 570                 575

Gln Cys Ile Cys His Glu Gly Phe Thr Gly Leu Asp Cys Gly Gln His
            580                 585                 590

Ser Cys Pro Ser Asp Cys Asn Asn Leu Gly Gln Cys Val Ser Gly Arg
        595                 600                 605

Cys Ile Cys Asn Glu Gly Tyr Ser Gly Glu Asp Cys Ser Glu Val Ser
    610                 615                 620

Pro Pro Lys Asp Leu Val Val Thr Glu Val Thr Glu Glu Thr Val Asn
625                 630                 635                 640

Leu Ala Trp Asp Asn Glu Met Arg Val Thr Glu Tyr Leu Val Val Tyr
                645                 650                 655

Thr Pro Thr His Glu Gly Gly Leu Glu Met Gln Phe Arg Val Pro Gly
            660                 665                 670

Asp Gln Thr Ser Thr Ile Ile Gln Glu Leu Glu Pro Gly Val Glu Tyr
        675                 680                 685

Phe Ile Arg Val Phe Ala Ile Leu Glu Asn Lys Lys Ser Ile Pro Val
    690                 695                 700

Ser Ala Arg Val Ala Thr Tyr Leu Pro Ala Pro Glu Gly Leu Lys Phe
```

-continued

```
705                 710                 715                 720

Lys Ser Ile Lys Glu Thr Ser Val Glu Val Glu Trp Asp Pro Leu Asp
                725                 730                 735

Ile Ala Phe Glu Thr Trp Glu Ile Ile Phe Arg Asn Met Asn Lys Glu
            740                 745                 750

Asp Glu Gly Glu Ile Thr Lys Ser Leu Arg Arg Pro Glu Thr Ser Tyr
        755                 760                 765

Arg Gln Thr Gly Leu Ala Pro Gly Gln Glu Tyr Glu Ile Ser Leu His
    770                 775                 780

Ile Val Lys Asn Asn Thr Arg Gly Pro Gly Leu Lys Arg Val Thr Thr
785                 790                 795                 800

Thr Arg Leu Asp Ala Pro Ser Gln Ile Glu Val Lys Asp Val Thr Asp
                805                 810                 815

Thr Thr Ala Leu Ile Thr Trp Phe Lys Pro Leu Ala Glu Ile Asp Gly
            820                 825                 830

Ile Glu Leu Thr Tyr Gly Ile Lys Asp Val Pro Gly Asp Arg Thr Thr
        835                 840                 845

Ile Asp Leu Thr Glu Asp Glu Asn Gln Tyr Ser Ile Gly Asn Leu Lys
    850                 855                 860

Pro Asp Thr Glu Tyr Glu Val Ser Leu Ile Ser Arg Arg Gly Asp Met
865                 870                 875                 880

Ser Ser Asn Pro Ala Lys Glu Thr Phe Thr Thr Gly Leu Asp Ala Pro
                885                 890                 895

Arg Asn Leu Arg Arg Val Ser Gln Thr Asp Asn Ser Ile Thr Leu Glu
            900                 905                 910

Trp Arg Asn Gly Lys Ala Ala Ile Asp Ser Tyr Arg Ile Lys Tyr Ala
        915                 920                 925

Pro Ile Ser Gly Gly Asp His Ala Glu Val Asp Val Pro Lys Ser Gln
    930                 935                 940

Gln Ala Thr Thr Lys Thr Thr Leu Thr Gly Leu Arg Pro Gly Thr Glu
945                 950                 955                 960

Tyr Gly Ile Gly Val Ser Ala Val Lys Glu Asp Lys Glu Ser Asn Pro
                965                 970                 975

Ala Thr Ile Asn Ala Ala Thr Glu Leu Asp Thr Pro Lys Asp Leu Gln
            980                 985                 990

Val Ser Glu Thr Ala Glu Thr Ser  Leu Thr Leu Leu Trp  Lys Thr Pro
        995                 1000                1005

Leu Ala  Lys Phe Asp Arg Tyr  Arg Leu Asn Tyr Ser  Leu Pro Thr
    1010                1015                1020

Gly Gln  Trp Val Gly Val Gln  Leu Pro Arg Asn Thr  Thr Ser Tyr
    1025                1030                1035

Val Leu  Arg Gly Leu Glu Pro  Gly Gln Glu Tyr Asn  Val Leu Leu
    1040                1045                1050

Thr Ala  Glu Lys Gly Arg His  Lys Ser Lys Pro Ala  Arg Val Lys
    1055                1060                1065

Ala Ser  Thr Glu Gln Ala Pro  Glu Leu Glu Asn Leu  Thr Val Thr
    1070                1075                1080

Glu Val  Gly Trp Asp Gly Leu  Arg Leu Asn Trp Thr  Ala Ala Asp
    1085                1090                1095

Gln Ala  Tyr Glu His Phe Ile  Ile Gln Val Gln Glu  Ala Asn Lys
    1100                1105                1110
```

-continued

```
Val Glu  Ala Ala Arg Asn Leu  Thr Val Pro Gly Ser  Leu Arg Ala
    1115                 1120                 1125

Val Asp  Ile Pro Gly Leu Lys  Ala Ala Thr Pro Tyr  Thr Val Ser
    1130                 1135                 1140

Ile Tyr  Gly Val Ile Gln Gly  Tyr Arg Thr Pro Val  Leu Ser Ala
    1145                 1150                 1155

Glu Ala  Ser Thr Gly Glu Thr  Pro Asn Leu Gly Glu  Val Val Val
    1160                 1165                 1170

Ala Glu  Val Gly Trp Asp Ala  Leu Lys Leu Asn Trp  Thr Ala Pro
    1175                 1180                 1185

Glu Gly  Ala Tyr Glu Tyr Phe  Phe Ile Gln Val Gln  Glu Ala Asp
    1190                 1195                 1200

Thr Val  Glu Ala Ala Gln Asn  Leu Thr Val Pro Gly  Gly Leu Arg
    1205                 1210                 1215

Ser Thr  Asp Leu Pro Gly Leu  Lys Ala Ala Thr His  Tyr Thr Ile
    1220                 1225                 1230

Thr Ile  Arg Gly Val Thr Gln  Asp Phe Ser Thr Thr  Pro Leu Ser
    1235                 1240                 1245

Val Glu  Val Leu Thr Glu Glu  Val Pro Asp Met Gly  Asn Leu Thr
    1250                 1255                 1260

Val Thr  Glu Val Ser Trp Asp  Ala Leu Arg Leu Asn  Trp Thr Thr
    1265                 1270                 1275

Pro Asp  Gly Thr Tyr Asp Gln  Phe Thr Ile Gln Val  Gln Glu Ala
    1280                 1285                 1290

Asp Gln  Val Glu Glu Ala His  Asn Leu Thr Val Pro  Gly Ser Leu
    1295                 1300                 1305

Arg Ser  Met Glu Ile Pro Gly  Leu Arg Ala Gly Thr  Pro Tyr Thr
    1310                 1315                 1320

Val Thr  Leu His Gly Glu Val  Arg Gly His Ser Thr  Arg Pro Leu
    1325                 1330                 1335

Ala Val  Glu Val Val Thr Glu  Asp Leu Pro Gln Leu  Gly Asp Leu
    1340                 1345                 1350

Ala Val  Ser Glu Val Gly Trp  Asp Gly Leu Arg Leu  Asn Trp Thr
    1355                 1360                 1365

Ala Ala  Asp Asn Ala Tyr Glu  His Phe Val Gln Val  Gln Glu Val
    1370                 1375                 1380

Asn Lys  Val Glu Ala Ala Gln  Asn Leu Thr Leu Pro  Gly Ser Leu
    1385                 1390                 1395

Arg Ala  Val Asp Ile Pro Gly  Leu Glu Ala Ala Thr  Pro Tyr Arg
    1400                 1405                 1410

Val Ser  Ile Tyr Gly Val Ile  Arg Gly Tyr Arg Thr  Pro Val Leu
    1415                 1420                 1425

Ser Ala  Glu Ala Ser Thr Ala  Lys Glu Pro Glu Ile  Gly Asn Leu
    1430                 1435                 1440

Asn Val  Ser Asp Ile Thr Pro  Glu Ser Phe Asn Leu  Ser Trp Met
    1445                 1450                 1455

Ala Thr  Asp Gly Ile Phe Glu  Thr Phe Thr Ile Glu  Ile Ile Asp
    1460                 1465                 1470

Ser Asn  Arg Leu Leu Glu Thr  Val Glu Tyr Asn Ile  Ser Gly Ala
    1475                 1480                 1485
```

-continued

```
Glu Arg  Thr Ala His Ile Ser  Gly Leu Pro Pro Ser  Thr Asp Phe
    1490                1495                1500

Ile Val  Tyr Leu Ser Gly Leu  Ala Pro Ser Ile Arg  Thr Lys Thr
    1505                1510                1515

Ile Ser  Ala Thr Ala Thr Thr  Glu Ala Leu Pro Leu  Leu Glu Asn
    1520                1525                1530

Leu Thr  Ile Ser Asp Ile Asn  Pro Tyr Gly Phe Thr  Val Ser Trp
    1535                1540                1545

Met Ala  Ser Glu Asn Ala Phe  Asp Ser Phe Leu Val  Thr Val Val
    1550                1555                1560

Asp Ser  Gly Lys Leu Leu Asp  Pro Gln Glu Phe Thr  Leu Ser Gly
    1565                1570                1575

Thr Gln  Arg Lys Leu Glu Leu  Arg Gly Leu Ile Thr  Gly Ile Gly
    1580                1585                1590

Tyr Glu  Val Met Val Ser Gly  Phe Thr Gln Gly His  Gln Thr Lys
    1595                1600                1605

Pro Leu  Arg Ala Glu Ile Val  Thr Glu Ala Glu Pro  Glu Val Asp
    1610                1615                1620

Asn Leu  Leu Val Ser Asp Ala  Thr Pro Asp Gly Phe  Arg Leu Ser
    1625                1630                1635

Trp Thr  Ala Asp Glu Gly Val  Phe Asp Asn Phe Val  Leu Lys Ile
    1640                1645                1650

Arg Asp  Thr Lys Lys Gln Ser  Glu Pro Leu Glu Ile  Thr Leu Leu
    1655                1660                1665

Ala Pro  Glu Arg Thr Arg Asp  Leu Thr Gly Leu Arg  Glu Ala Thr
    1670                1675                1680

Glu Tyr  Glu Ile Glu Leu Tyr  Gly Ile Ser Lys Gly  Arg Arg Ser
    1685                1690                1695

Gln Thr  Val Ser Ala Ile Ala  Thr Thr Ala Met Gly  Ser Pro Lys
    1700                1705                1710

Glu Val  Ile Phe Ser Asp Ile  Thr Glu Asn Ser Ala  Thr Val Ser
    1715                1720                1725

Trp Arg  Ala Pro Thr Ala Gln  Val Glu Ser Phe Arg  Ile Thr Tyr
    1730                1735                1740

Val Pro  Ile Thr Gly Gly Thr  Pro Ser Met Val Thr  Val Asp Gly
    1745                1750                1755

Thr Lys  Thr Gln Thr Arg Leu  Val Lys Leu Ile Pro  Gly Val Glu
    1760                1765                1770

Tyr Leu  Val Ser Ile Ile Ala  Met Lys Gly Phe Glu  Glu Ser Glu
    1775                1780                1785

Pro Val  Ser Gly Ser Phe Thr  Thr Ala Leu Asp Gly  Pro Ser Gly
    1790                1795                1800

Leu Val  Thr Ala Asn Ile Thr  Asp Ser Glu Ala Leu  Ala Arg Trp
    1805                1810                1815

Gln Pro  Ala Ile Ala Thr Val  Asp Ser Tyr Val Ile  Ser Tyr Thr
    1820                1825                1830

Gly Glu  Lys Val Pro Glu Ile  Thr Arg Thr Val Ser  Gly Asn Thr
    1835                1840                1845

Val Glu  Tyr Ala Leu Thr Asp  Leu Glu Pro Ala Thr  Glu Tyr Thr
    1850                1855                1860

Leu Arg  Ile Phe Ala Glu Lys  Gly Pro Gln Lys Ser  Ser Thr Ile
```

-continued

```
    1865                1870                1875

Thr Ala  Lys Phe Thr Thr Asp  Leu Asp Ser Pro Arg  Asp Leu Thr
    1880                1885                1890

Ala Thr  Glu Val Gln Ser Glu  Thr Ala Leu Leu Thr  Trp Arg Pro
    1895                1900                1905

Pro Arg  Ala Ser Val Thr Gly  Tyr Leu Leu Val Tyr  Glu Ser Val
    1910                1915                1920

Asp Gly  Thr Val Lys Glu Val  Ile Val Gly Pro Asp  Thr Thr Ser
    1925                1930                1935

Tyr Ser  Leu Ala Asp Leu Ser  Pro Ser Thr His Tyr  Thr Ala Lys
    1940                1945                1950

Ile Gln  Ala Leu Asn Gly Pro  Leu Arg Ser Asn Met  Ile Gln Thr
    1955                1960                1965

Ile Phe  Thr Thr Ile Gly Leu  Leu Tyr Pro Phe Pro  Lys Asp Cys
    1970                1975                1980

Ser Gln  Ala Met Leu Asn Gly  Asp Thr Thr Ser Gly  Leu Tyr Thr
    1985                1990                1995

Ile Tyr  Leu Asn Gly Asp Lys  Ala Gln Ala Leu Glu  Val Phe Cys
    2000                2005                2010

Asp Met  Thr Ser Asp Gly Gly  Gly Trp Ile Val Phe  Leu Arg Arg
    2015                2020                2025

Lys Asn  Gly Arg Glu Asn Phe  Tyr Gln Asn Trp Lys  Ala Tyr Ala
    2030                2035                2040

Ala Gly  Phe Gly Asp Arg Arg  Glu Glu Phe Trp Leu  Gly Leu Asp
    2045                2050                2055

Asn Leu  Asn Lys Ile Thr Ala  Gln Gly Gln Tyr Glu  Leu Arg Val
    2060                2065                2070

Asp Leu  Arg Asp His Gly Glu  Thr Ala Phe Ala Val  Tyr Asp Lys
    2075                2080                2085

Phe Ser  Val Gly Asp Ala Lys  Thr Arg Tyr Lys Leu  Lys Val Glu
    2090                2095                2100

Gly Tyr  Ser Gly Thr Ala Gly  Asp Ser Met Ala Tyr  His Asn Gly
    2105                2110                2115

Arg Ser  Phe Ser Thr Phe Asp  Lys Asp Thr Asp Ser  Ala Ile Thr
    2120                2125                2130

Asn Cys  Ala Leu Ser Tyr Lys  Gly Ala Phe Trp Tyr  Arg Asn Cys
    2135                2140                2145

His Arg  Val Asn Leu Met Gly  Arg Tyr Gly Asp Asn  Asn His Ser
    2150                2155                2160

Gln Gly  Val Asn Trp Phe His  Trp Lys Gly His Glu  His Ser Ile
    2165                2170                2175

Gln Phe  Ala Glu Met Lys Leu  Arg Pro Ser Asn Phe  Arg Asn Leu
    2180                2185                2190

Glu Gly  Arg Arg Lys Arg Ala
    2195                2200


<210> SEQ ID NO 3
<211> LENGTH: 8578
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Supplied by Invitrogen of Carlsbad, California
```

-continued

<400> SEQUENCE: 3

gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctagc 900

gtttaaactt aagcttacca tgggggggttc tcatcatcat catcatcatg gtatggctag 960

catgactggt ggacagcaaa tgggtcggga tctgtacgac gatgacgata aggtacctaa 1020

ggatcagctt ggagttgatc ccgtcgtttt acaacgtcgt gactgggaaa accctggcgt 1080

tacccaactt aatcgccttg cagcacatcc cctttcgcc agctggcgta atagcgaaga 1140

ggcccgcacc gatcgccctt cccaacagtt gcgcagcctg aatggcgaat ggcgctttgc 1200

ctggtttccg gcaccagaag cggtgccgga aagctggctg gagtgcgatc ttcctgaggc 1260

cgatactgtc gtcgtcccct caaactggca gatgcacggt tacgatgcgc ccatctacac 1320

caacgtaacc tatcccatta cggtcaatcc gccgtttgtt cccacggaga atccgacggg 1380

ttgttactcg ctcacattta atgttgatga aagctggcta caggaaggcc agacgcgaat 1440

tatttttgat ggcgttaact cggcgtttca tctgtggtgc aacgggcgct gggtcggtta 1500

cggccaggac agtcgtttgc cgtctgaatt tgacctgagc gcatttttac gcgccggaga 1560

aaaccgcctc gcggtgatgg tgctgcgttg gagtgacggc agttatctgg aagatcagga 1620

tatgtggcgg atgagcggca ttttccgtga cgtctcgttg ctgcataaac cgactacaca 1680

aatcagcgat ttccatgttg ccactcgctt taatgatgat ttcagccgcg ctgtactgga 1740

ggctgaagtt cagatgtgcg gcgagttgcg tgactaccta cgggtaacag tttctttatg 1800

gcagggtgaa acgcaggtcg ccagcggcac cgcgcctttc ggcggtgaaa ttatcgatga 1860

gcgtggtggt tatgccgatc gcgtcacact acgtctgaac gtcgaaaacc cgaaactgtg 1920

gagcgccgaa atcccgaatc tctatcgtgc ggtggttgaa ctgcacaccg ccgacggcac 1980

gctgattgaa gcagaagcct gcgatgtcgg tttccgcgag gtgcggattg aaaatggtct 2040

gctgctgctg aacggcaagc cgttgctgat tcgaggcgtt aaccgtcacg agcatcatcc 2100

tctgcatggt caggtcatgg atgagcagac gatggtgcag gatatcctgc tgatgaagca 2160

gaacaacttt aacgccgtgc gctgttcgca ttatccgaac catccgctgt ggtacacgct 2220

-continued

gtgcgaccgc tacggcctgt atgtggtgga tgaagccaat attgaaaccc acggcatggt 2280

gccaatgaat cgtctgaccg atgatccgcg ctggctaccg gcgatgagcg aacgcgtaac 2340

gcgaatggtg cagcgcgatc gtaatcaccc gagtgtgatc atctggtcgc tggggaatga 2400

atcaggccac ggcgctaatc acgacgcgct gtatcgctgg atcaaatctg tcgatccttc 2460

ccgcccggtg cagtatgaag gcggcggagc cgacaccacg gccaccgata ttatttgccc 2520

gatgtacgcg cgcgtggatg aagaccagcc cttcccggct gtgccgaaat ggtccatcaa 2580

aaaatggctt tcgctacctg gagagacgcg cccgctgatc ctttgcgaat acgcccacgc 2640

gatgggtaac agtcttggcg gtttcgctaa atactggcag gcgtttcgtc agtatccccg 2700

tttacagggc ggcttcgtct gggactgggt ggatcagtcg ctgattaaat atgatgaaaa 2760

cggcaacccg tggtcggctt acggcggtga ttttggcgat acgccgaacg atcgccagtt 2820

ctgtatgaac ggtctggtct ttgccgaccg cacgccgcat ccagcgctga cggaagcaaa 2880

acaccagcag cagtttttcc agttccgttt atccgggcaa accatcgaag tgaccagcga 2940

atacctgttc cgtcatagcg ataacgagct cctgcactgg atggtggcgc tggatggtaa 3000

gccgctggca agcggtgaag tgcctctgga tgtcgctcca caaggtaaac agttgattga 3060

actgcctgaa ctaccgcagc cggagagcgc cgggcaactc tggctcacag tacgcgtagt 3120

gcaaccgaac gcgaccgcat ggtcagaagc cgggcacatc agcgcctggc agcagtggcg 3180

tctggcggaa aacctcagtg tgacgctccc cgccgcgtcc cacgccatcc cgcatctgac 3240

caccagcgaa atggattttt gcatcgagct gggtaataag cgttggcaat ttaaccgcca 3300

gtcaggcttt ctttcacaga tgtggattgg cgataaaaaa caactgctga cgccgctgcg 3360

cgatcagttc acccgtgcac cgctggataa cgacattggc gtaagtgaag cgacccgcat 3420

tgaccctaac gcctgggtcg aacgctggaa ggcggcgggc cattaccagg ccgaagcagc 3480

gttgttgcag tgcacggcag atacacttgc tgatgcggtg ctgattacga ccgctcacgc 3540

gtggcagcat cagggaaaa ccttatttat cagccggaaa acctaccgga ttgatggtag 3600

tggtcaaatg gcgattaccg ttgatgttga agtggcgagc gatacaccgc atccggcgcg 3660

gattggcctg aactgccagc tggcgcaggt agcagagcgg gtaaactggc tcggattagg 3720

gccgcaagaa aactatcccg accgccttac tgccgcctgt tttgaccgct gggatctgcc 3780

attgtcagac atgtataccc cgtacgtctt cccgagcgaa aacggtctgc gctgcgggac 3840

gcgcgaattg aattatggcc cacaccagtg gcgcggcgac ttccagttca acatcagccg 3900

ctacagtcaa cagcaactga tggaaaccag ccatcgccat ctgctgcacg cggaagaagg 3960

cacatggctg aatatcgacg gtttccatat ggggattggt ggcgacgact cctggagccc 4020

gtcagtatcg gcggagttcc agctgagcgc cggtcgctac cattaccagt tggtctggtg 4080

tcaaaaataa taaagccgaa ttctgcagat atccagcaca gtggcggccg ctcgagtcta 4140

gagggcccgt ttaaacccgc tgatcagcct cgactgtgcc ttctagttgc cagccatctg 4200

ttgtttgccc ctccccgtg ccttccttga ccctggaagg tgccactccc actgtccttt 4260

cctaataaaa tgaggaaatt gcatcgcatt gtctgagtag gtgtcattct attctggggg 4320

gtggggtggg gcaggacagc aaggggagg attgggaaga caatagcagg catgctgggg 4380

atgcggtggg ctctatggct tctgaggcgg aaagaaccag ctggggctct aggggtatc 4440

cccacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga 4500

-continued

ccgctacact tgccagcgcc ctagcgcccg ctcctttcgc tttcttccct tcctttctcg 4560

ccacgttcgc cggctttccc cgtcaagctc taaatcgggg catcccttta gggttccgat 4620

ttagtgcttt acggcacctc gaccccaaaa aacttgatta gggtgatggt tcacgtagtg 4680

ggccatcgcc ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg ttctttaata 4740

gtggactctt gttccaaact ggaacaacac tcaaccctat ctcggtctat tcttttgatt 4800

tataagggat tttggggatt tcggcctatt ggttaaaaaa tgagctgatt taacaaaaat 4860

ttaacgcgaa ttaattctgt ggaatgtgtg tcagttaggg tgtggaaagt ccccaggctc 4920

cccaggcagg cagaagtatg caaagcatgc atctcaatta gtcagcaacc aggtgtggaa 4980

agtccccagg ctccccagca ggcagaagta tgcaaagcat gcatctcaat tagtcagcaa 5040

ccatagtccc gcccctaact ccgcccatcc cgcccctaac tccgcccagt tccgcccatt 5100

ctccgcccca tggctgacta attttttta tttatgcaga ggccgaggcc gcctctgcct 5160

ctgagctatt ccagaagtag tgaggaggct tttttggagg cctaggcttt tgcaaaaagc 5220

tcccgggagc ttgtatatcc attttcggat ctgatcaaga gacaggatga ggatcgtttc 5280

gcatgattga acaagatgga ttgcacgcag gttctccggc cgcttgggtg gagaggctat 5340

tcggctatga ctgggcacaa cagacaatcg gctgctctga tgccgccgtg ttccggctgt 5400

cagcgcaggg gcgcccggtt ctttttgtca agaccgacct gtccggtgcc ctgaatgaac 5460

tgcaggacga ggcagcgcgg ctatcgtggc tggccacgac gggcgttcct tgcgcagctg 5520

tgctcgacgt tgtcactgaa gcgggaaggg actggctgct attgggcgaa gtgccggggc 5580

aggatctcct gtcatctcac cttgctcctg ccgagaaagt atccatcatg gctgatgcaa 5640

tgcggcggct gcatacgctt gatccggcta cctgcccatt cgaccaccaa gcgaaacatc 5700

gcatcgagcg agcacgtact cggatggaag ccggtcttgt cgatcaggat gatctggacg 5760

aagagcatca ggggctcgcg ccagccgaac tgttcgccag gctcaaggcg cgcatgcccg 5820

acggcgagga tctcgtcgtg acccatggcg atgcctgctt gccgaatatc atggtggaaa 5880

atggccgctt ttctggattc atcgactgtg gccggctggg tgtggcggac cgctatcagg 5940

acatagcgtt ggctacccgt gatattgctg aagagcttgg cggcgaatgg gctgaccgct 6000

tcctcgtgct ttacggtatc gccgctcccg attcgcagcg catcgccttc tatcgccttc 6060

ttgacgagtt cttctgagcg ggactctggg gttcgaaatg accgaccaag cgacgcccaa 6120

cctgccatca cgagatttcg attccaccgc cgccttctat gaaaggttgg gcttcggaat 6180

cgttttccgg gacgccggct ggatgatcct ccagcgcggg gatctcatgc tggagttctt 6240

cgcccacccc aacttgttta ttgcagctta taatggttac aaataaagca atagcatcac 6300

aaatttcaca aataaagcat ttttttcact gcattctagt tgtggtttgt ccaaactcat 6360

caatgtatct tatcatgtct gtataccgtc gacctctagc tagagcttgg cgtaatcatg 6420

gtcatagctg tttcctgtgt gaaattgtta tccgctcaca attccacaca acatacgagc 6480

cggaagcata aagtgtaaag cctggggtgc ctaatgagtg agctaactca cattaattgc 6540

gttgcgctca ctgcccgctt tccagtcggg aaacctgtcg tgccagctgc attaatgaat 6600

cggccaacgc gcggggagag gcggtttgcg tattgggcgc tcttccgctt cctcgctcac 6660

tgactcgctg cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt 6720

aatacggtta tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca 6780

-continued

gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc 6840

ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact 6900

ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct 6960

gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcaatg 7020

ctcacgctgt aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca 7080

cgaacccccc gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa 7140

cccggtaaga cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc 7200

gaggtatgta ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag 7260

aaggacagta tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg 7320

tagctcttga tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca 7380

gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc 7440

tgacgctcag tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag 7500

gatcttcacc tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata 7560

tgagtaaact tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat 7620

ctgtctattt cgttcatcca tagttgcctg actccccgtc gtgtagataa ctacgatacg 7680

ggagggctta ccatctggcc ccagtgctgc aatgataccg cgagacccac gctcaccggc 7740

tccagattta tcagcaataa accagccagc cggaagggcc gagcgcagaa gtggtcctgc 7800

aactttatcc gcctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc 7860

gccagttaat agtttgcgca acgttgttgc cattgctaca ggcatcgtgg tgtcacgctc 7920

gtcgtttggt atggcttcat tcagctccgg ttcccaacga tcaaggcgag ttacatgatc 7980

ccccatgttg tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg tcagaagtaa 8040

gttggccgca gtgttatcac tcatggttat ggcagcactg cataattctc ttactgtcat 8100

gccatccgta agatgctttt ctgtgactgg tgagtactca accaagtcat tctgagaata 8160

gtgtatgcgg cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca 8220

tagcagaact ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa aactctcaag 8280

gatcttaccg ctgttgagat ccagttcgat gtaacccact cgtgcaccca actgatcttc 8340

agcatctttt actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc 8400

aaaaaaggga ataagggcga cacggaaatg ttgaatactc atactcttcc tttttcaata 8460

ttattgaagc atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta 8520

gaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgccac ctgacgtc 8578

<210> SEQ ID NO 4
<211> LENGTH: 4748
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Provided by Dr. Brett Levay-Young of the University of Minnesota

<400> SEQUENCE: 4

tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg 60

cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt 120

gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca 180

-continued

atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc 240

aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta 300

catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac 360

catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg 420

atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg 480

ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt 540

acggtgggag gtctatataa gcagagctgg tttagtgaac cgtcagatcc gctagcgcta 600

ccggtcgcca ccatggtgag caagggcgag gagctgttca ccggggtggt gcccatcctg 660

gtcgagctgg acggcgacgt aaacggccac aagttcagcg tgtccggcga gggcgagggc 720

gatgccacct acggcaagct gaccctgaag ttcatctgca ccaccggcaa gctgcccgtg 780

ccctggccca ccctcgtgac caccctgacc tacggcgtgc agtgcttcag ccgctacccc 840

gaccacatga agcagcacga cttcttcaag tccgccatgc ccgaaggcta cgtccaggag 900

cgcaccatct tcttcaagga cgacggcaac tacaagaccc gcgccgaggt gaagttcgag 960

ggcgacaccc tggtgaaccg catcgagctg aagggcatcg acttcaagga ggacggcaac 1020

atcctggggc acaagctgga gtacaactac aacagccaca acgtctatat catggccgac 1080

aagcagaaga acggcatcaa ggtgaacttc aagatccgcc acaacatcga ggacggcagc 1140

gtgcagctcg ccgaccacta ccagcagaac accccccatcg gcgacggccc cgtgctgctg 1200

cccgacaacc actacctgag cacccagtcc gccctgagca aagaccccaa cgagaagcgc 1260

gatcacatgg tcctgctgga gttcgtgacc gccgccggga tcactctcgg catggacgag 1320

ctgtacaagt actcagatct cgagctcaag cttaaccctc cggacgagag cggccctggc 1380

tgtatgtcct gcaagtgcgt gctgtcctga tcaccggatc tagataactg atcataatca 1440

gccataccac atttgtagag gttttacttg ctttaaaaaa cctcccacac ctccccctga 1500

acctgaaaca taaaatgaat gcaattgttg ttgttaactt gtttattgca gcttataatg 1560

gttacaaata aagcaatagc atcacaaatt tcacaaataa agcatttttt tcactgcatt 1620

ctagttgtgg tttgtccaaa ctcatcaatg tatcttaacg cgtaaattgt aagcgttaat 1680

attttgttaa aattcgcgtt aaatttttgt taaatcagct catttttaa ccaataggcc 1740

gaaatcggca aaatccctta taaatcaaaa gaatagaccg agatagggtt gagtgttgtt 1800

ccagtttgga acaagagtcc actattaaag aacgtggact ccaacgtcaa agggcgaaaa 1860

accgtctatc agggcgatgg cccactacgt gaaccatcac cctaatcaag ttttttgggg 1920

tcgaggtgcc gtaaagcact aaatcggaac cctaaaggga gcccccgatt tagagcttga 1980

cggggaaagc cggcgaacgt ggcgagaaag gaagggaaga aagcgaaagg agcgggcgct 2040

agggcgctgg caagtgtagc ggtcacgctg cgcgtaacca ccacacccgc cgcgcttaat 2100

gcgccgctac agggcgcgtc aggtggcact tttcggggaa atgtgcgcgg aacccctatt 2160

tgtttatttt tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa 2220

atgcttcaat aatattgaaa aaggaagagt cctgaggcgg aaagaaccag ctgtggaatg 2280

tgtgtcagtt agggtgtgga aagtccccag gctccccagc aggcagaagt atgcaaagca 2340

tgcatctcaa ttagtcagca accaggtgtg gaaagtcccc aggctcccca gcaggcagaa 2400

gtatgcaaag catgcatctc aattagtcag caaccatagt cccgccccta actccgccca 2460

-continued

```
tcccgcccct aactccgccc agttccgccc attctccgcc ccatggctga ctaatttttt   2520

ttatttatgc agaggccgag gccgcctcgg cctctgagct attccagaag tagtgaggag   2580

gctttttgg aggcctaggc ttttgcaaag atcgatcaag agacaggatg aggatcgttt   2640

cgcatgattg aacaagatgg attgcacgca ggttctccgg ccgcttgggt ggagaggcta   2700

ttcggctatg actgggcaca acagacaatc ggctgctctg atgccgccgt gttccggctg   2760

tcagcgcagg ggcgcccggt tctttttgtc aagaccgacc tgtccggtgc cctgaatgaa   2820

ctgcaagacg aggcagcgcg gctatcgtgg ctggccacga cgggcgttcc ttgcgcagct   2880

gtgctcgacg ttgtcactga agcgggaagg gactggctgc tattgggcga agtgccgggg   2940

caggatctcc tgtcatctca ccttgctcct gccgagaaag tatccatcat ggctgatgca   3000

atgcggcggc tgcatacgct tgatccggct acctgcccat tcgaccacca agcgaaacat   3060

cgcatcgagc gagcacgtac tcggatggaa gccggtcttg tcgatcagga tgatctggac   3120

gaagagcatc aggggctcgc gccagccgaa ctgttcgcca ggctcaaggc gagcatgccc   3180

gacggcgagg atctcgtcgt gacccatggc gatgcctgct tgccgaatat catggtggaa   3240

aatggccgct tttctggatt catcgactgt ggccggctgg gtgtggcgga ccgctatcag   3300

gacatagcgt tggctacccg tgatattgct gaagagcttg gcggcgaatg ggctgaccgc   3360

ttcctcgtgc tttacggtat cgccgctccc gattcgcagc gcatcgcctt ctatcgcctt   3420

cttgacgagt tcttctgagc gggactctgg ggttcgaaat gaccgaccaa gcgacgccca   3480

acctgccatc acgagatttc gattccaccg ccgccttcta tgaaaggttg ggcttcggaa   3540

tcgttttccg ggacgccggc tggatgatcc tccagcgcgg ggatctcatg ctggagttct   3600

tcgcccaccc taggggggag ctaactgaaa cacggaagga gacaataccg gaaggaaccc   3660

gcgctatgac ggcaataaaa agacagaata aaacgcacgg tgttgggtcg tttgttcata   3720

aacgcggggt tcggtcccag ggctggcact ctgtcgatac cccaccgaga ccccattggg   3780

gccaatacgc ccgcgtttct tccttttccc caccccaccc cccaagttcg ggtgaaggcc   3840

cagggctcgc agccaacgtc ggggcggcag gccctgccat agcctcaggt tactcatata   3900

tactttagat tgatttaaaa cttcattttt aatttaaaag gatctaggtg aagatccttt   3960

ttgataatct catgaccaaa atcccttaac gtgagttttc gttccactga gcgtcagacc   4020

ccgtagaaaa gatcaaagga tcttcttgag atccttttttt tctgcgcgta atctgctgct   4080

tgcaaacaaa aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa   4140

ctcttttcc gaaggtaact ggcttcagca gagcgcagat accaaatact gtccttctag   4200

tgtagccgta gttaggccac cacttcaaga actctgtagc accgcctaca tacctcgctc   4260

tgctaatcct gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accgggttgg   4320

actcaagacg atagttaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca   4380

cacagcccag cttggagcga acgacctaca ccgaactgag atacctacag cgtgagctat   4440

gagaaagcgc cacgcttccc gaagggagaa aggcggacag gtatccggta agcggcaggg   4500

tcggaacagg agagcgcacg agggagcttc cagggggaaa cgcctggtat ctttatagtc   4560

ctgtcgggtt tcgccacctc tgacttgagc gtcgatttttt gtgatgctcg tcaggggggc   4620

ggagcctatg gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc   4680

cttttgctca catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg   4740
```

-continued

ccatgcat 4748

<210> SEQ ID NO 5
<211> LENGTH: 4992
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Supplied by BD Biosciences Clonetech of Palo Alto, California

<400> SEQUENCE: 5

tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg 60

cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt 120

gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca 180

atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc 240

aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta 300

catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac 360

catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg 420

atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg 480

ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt 540

acggtgggag gtctatataa gcagagctgg tttagtgaac cgtcagatcc gctagcgcta 600

ccggtcgcca ccatggtgag caagggcgag gagctgttca ccggggtggt gcccatcctg 660

gtcgagctgg acggcgacgt aaacggccac aagttcagcg tgtccggcga gggcgagggc 720

gatgccacct acggcaagct gaccctgaag ttcatctgca ccaccggcaa gctgcccgtg 780

ccctggccca ccctcgtgac caccctgacc tacggcgtgc agtgcttcag ccgctacccc 840

gaccacatga agcagcacga cttcttcaag tccgccatgc ccgaaggcta cgtccaggag 900

cgcaccatct tcttcaagga cgacggcaac tacaagaccc gcgccgaggt gaagttcgag 960

ggcgacaccc tggtgaaccg catcgagctg aagggcatcg acttcaagga ggacggcaac 1020

atcctggggc acaagctgga gtacaactac aacagccaca acgtctatat catggccgac 1080

aagcagaaga acggcatcaa ggtgaacttc aagatccgcc acaacatcga ggacggcagc 1140

gtgcagctcg ccgaccacta ccagcagaac accccatcg gcgacggccc cgtgctgctg 1200

cccgacaacc actacctgag cacccagtcc gccctgagca aagaccccaa cgagaagcgc 1260

gatcacatgg tcctgctgga gttcgtgacc gccgccggga tcactctcgg catggacgag 1320

ctgtacaagt actcagatct cgagctcaag cttaccatgg ggggttctca tcatcatcat 1380

catcatggta tggctagcat gactggtgga cagcaaatgg gtcgggatct gtacgacgat 1440

gacgataagg ggactgctgc ggccaatgcg aacgacttct tcgccaagcg caagagaact 1500

gcgcaggaga acaaggcgtc gaacgacgtc cctccagggt gtccctctcc aaacgtggct 1560

cctggggtgg gcgcggtgga gcagaccccg cgcaaacgtc tgagatgagg atccagtgtg 1620

gtggaattct gcagatatcc agcacagtgg cggccgctcg agtctagata actgatcata 1680

atcagccata ccacatttgt agaggtttta cttgctttaa aaaacctccc acacctcccc 1740

ctgaacctga aacataaaat gaatgcaatt gttgttgtta acttgtttat tgcagcttat 1800

aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt tttttcactg 1860

-continued

cattctagtt gtggtttgtc caaactcatc aatgtatctt aacgcgtaaa ttgtaagcgt 1920

taatattttg ttaaaattcg cgttaaattt ttgttaaatc agctcatttt ttaaccaata 1980

ggccgaaatc ggcaaaatcc cttataaatc aaaagaatag accgagatag ggttgagtgt 2040

tgttccagtt tggaacaaga gtccactatt aaagaacgtg gactccaacg tcaaagggcg 2100

aaaaaccgtc tatcagggcg atggcccact acgtgaacca tcaccctaat caagtttttt 2160

ggggtcgagg tgccgtaaag cactaaatcg gaaccctaaa gggagccccc gatttagagc 2220

ttgacgggga aagccggcga acgtggcgag aaaggaaggg aagaaagcga aaggagcggg 2280

cgctagggcg ctggcaagtg tagcggtcac gctgcgcgta accaccacac ccgccgcgct 2340

taatgcgccg ctacagggcg cgtcaggtgg cacttttcgg ggaaatgtgc gcggaacccc 2400

tatttgttta tttttctaaa tacattcaaa tatgtatccg ctcatgagac aataaccctg 2460

ataaatgctt caataatatt gaaaaaggaa gagtcctgag gcggaaagaa ccagctgtgg 2520

aatgtgtgtc agttagggtg tggaaagtcc ccaggctccc cagcaggcag aagtatgcaa 2580

agcatgcatc tcaattagtc agcaaccagg tgtggaaagt ccccaggctc cccagcaggc 2640

agaagtatgc aaagcatgca tctcaattag tcagcaacca tagtcccgcc cctaactccg 2700

cccatcccgc ccctaactcc gcccagttcc gcccattctc cgccccatgg ctgactaatt 2760

ttttttattt atgcagaggc cgaggccgcc tcggcctctg agctattcca gaagtagtga 2820

ggaggctttt ttggaggcct aggcttttgc aaagatcgat caagagacag gatgaggatc 2880

gtttcgcatg attgaacaag atggattgca cgcaggttct ccggccgctt gggtggagag 2940

gctattcggc tatgactggg cacaacagac aatcggctgc tctgatgccg ccgtgttccg 3000

gctgtcagcg caggggcgcc cggttctttt tgtcaagacc gacctgtccg gtgccctgaa 3060

tgaactgcaa gacgaggcag cgcggctatc gtggctggcc acgacgggcg ttccttgcgc 3120

agctgtgctc gacgttgtca ctgaagcggg aagggactgg ctgctattgg gcgaagtgcc 3180

ggggcaggat ctcctgtcat ctcaccttgc tcctgccgag aaagtatcca tcatggctga 3240

tgcaatgcgg cggctgcata cgcttgatcc ggctacctgc ccattcgacc accaagcgaa 3300

acatcgcatc gagcgagcac gtactcggat ggaagccggt cttgtcgatc aggatgatct 3360

ggacgaagag catcaggggc tcgcgccagc cgaactgttc gccaggctca aggcgagcat 3420

gcccgacggc gaggatctcg tcgtgaccca tggcgatgcc tgcttgccga atatcatggt 3480

ggaaaatggc cgcttttctg gattcatcga ctgtggccgg ctgggtgtgg cggaccgcta 3540

tcaggacata gcgttggcta cccgtgatat tgctgaagag cttggcggcg aatgggctga 3600

ccgcttcctc gtgctttacg gtatcgccgc tcccgattcg cagcgcatcg ccttctatcg 3660

ccttcttgac gagttcttct gagcgggact ctggggttcg aaatgaccga ccaagcgacg 3720

cccaacctgc catcacgaga tttcgattcc accgccgcct tctatgaaag gttgggcttc 3780

ggaatcgttt tccgggacgc cggctggatg atcctccagc gcggggatct catgctggag 3840

ttcttcgccc accctagggg gaggctaact gaaacacgga aggagacaat accggaagga 3900

acccgcgcta tgacggcaat aaaaagacag aataaaacgc acggtgttgg gtcgtttgtt 3960

cataaacgcg gggttcggtc ccagggctgg cactctgtcg ataccccacc gagaccccat 4020

tggggccaat acgcccgcgt ttcttccttt tccccacccc acccccccaag ttcgggtgaa 4080

ggcccagggc tcgcagccaa cgtcggggcg gcaggccctg ccatagcctc aggttactca 4140

-continued

```
tatatacttt agattgattt aaaacttcat ttttaattta aaaggatcta ggtgaagatc   4200

ctttttgata atctcatgac caaaatccct taacgtgagt tttcgttcca ctgagcgtca   4260

gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg cgtaatctgc   4320

tgcttgcaaa caaaaaaacc accgctacca gcggtggttt gtttgccgga tcaagagcta   4380

ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa tactgtcctt   4440

ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc tacatacctc   4500

gctctgctaa tcctgttacc agtggctgct gccagtggcg ataagtcgtg tcttaccggg   4560

ttggactcaa gacgatagtt accggataag gcgcagcggt cgggctgaac gggggttcg    4620

tgcacacagc ccagcttgga gcgaacgacc tacaccgaac tgagatacct acagcgtgag   4680

ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc ggtaagcggc   4740

agggtcggaa caggagagcg cacgagggag cttccagggg gaaacgcctg gtatctttat   4800

agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg ctcgtcaggg   4860

gggcggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttcct ggccttttgc   4920

tggccttttg ctcacatgtt ctttcctgcg ttatcccctg attctgtgga taaccgtatt   4980

accgccatgc at                                                      4992
```

1. A composition comprising:

a plurality of particles comprising a surfactant having an HLB value of less than about 6.0 units associated with a functional composition and a polymer, with the particles having an average diameter of less than about 100 nanometers as measured by atomic force microscopy of the particles following drying of the particles, wherein the functional composition is a member of the group consisting of a bioactive component and a diagnostic agent.

2. The composition of claim 1 wherein the surfactant is a non-ionic surfactant.

3. The composition of claim 1 wherein the surfactant has an HLB value of less than about 5.0 units.

4. The composition of claim 3 wherein the average diameter of the particles is less than about 50 nm.

5. The composition of claim 1 wherein the functional composition is a member of the group consisting of peptides, proteins, and carbohydrates.

6. The composition of claim 5 wherein the average diameter is less than about 50 nm.

7. The composition of claim 1 wherein the functional composition is cisplatin.

8. The composition of claim 1 wherein the functional composition is inorganic.

9. The composition of claim 1 wherein the functional composition is a diagnostic agent that is a fluorescent molecule.

10. The composition of claim 1 wherein the functional composition is a bioactive component that comprises a hydrophilic component.

11. The composition of claim 10 wherein the bioactive component is condensed.

12. The composition of claim 1 wherein the functional composition is a bioactive component that is a member of the group consisting of aptamers, mini-chromosomes, steroids, adrenergic, adrenocotical steroid, adrenocortical suppressant, aldosterone antagonist, and anabolic agents; analeptic, analgesic, anesthetic, anorectic, anti-acne agents; anti-adrenergic, anti-allergic, anti-amebic, anti-anemic, and anti-anginal agents; anti-arthritic, anti-asthmatic, anti-atherosclerotic, antibacterial, and anticholinergic agents; anticoagulant, anticonvulsant, antidepressant, antidiabetic, and antidiarrheal agents; antidiuretic, anti-emetic, anti-epileptic, antifibrinolytic, and antifungal agent; antihemorrhagic, inflammatory, antimicrobial, antimigraine, and antimiotic agents; antimycotic, antinauseant, antineoplastic, antineutropenic, and antiparasitic agents; antiproliferative, antipsychotic, antirheumatic, antiseborrheic, and antisecretory agents; antipasmodic, antihrombotic, anti-ulcerative, antiviral and appetite suppressant agents.

13. The composition of claim 1 wherein the functional composition is a bioactive component that is a member of the group consisting of blood glucose regulator, bone resorption inhibitor, bronchodilator, cardiovascular, and cholinergic agents; fluorescent, free oxygen radical scavenger, gastrointestinal motility effector, glucocorticoid, and hair growth stimulant agent; hemostatic, histamine H_2 receptor antagonists; hormone; hypocholesterolemic, and hypoglycemic agents; hypolipidemic, hypotensive, and imaging agents, immunizing and agonist agents; mood regulators, mucolytic, mydriatic, nasal decongestant; neuromuscular blocking agents; neuroprotective, NMDA antagonist, nonhormonal sterol derivative, plasminogen activator, and platelet activating factor antagonist agent.

14. The composition of claim 1 wherein the functional composition is a bioactive component that is a member of the group consisting of platelet aggregation inhibitor, psychotropic, radioactive, scabicide, and sclerosing agents; sedative, sedative-hypnotic, selective adenosine A1 antagonist, serotonin antagonist, and serotonin inhibitor agent;

serotonin receptor antagonist, steroid, thyroid hormone, thyroid hormone, thyroid inhibitor agent; thyromimetic, tranquilizer, amyotrophic lateral sclerosis, cerebral ischemia, Pagel's disease agent; unstable angina, vasoconstrictor, vasodilator, wound healing, and xanthine oxidase inhibitor agent; and immunological agents.

15. The composition of claim 1 wherein the functional composition is a bioactive component that comprises a member of the group consisting of antigens isolated from pathogens, viral antigens, fungal antigens, parasitic antigens, and inactivated pathogenic organisms.

16. The composition of claim 1 wherein the surfactant has a critical micelle concentration of less than about 200 micromolar.

17. The composition of claim 1 further comprising a biocompatible oil.

18. The composition of claim 1 wherein the functional composition is a bioactive component that comprises a polynucleic acid, oligonucleotide, antisense molecule, or a polypeptide.

19. The composition of claim 18 wherein the bioactive component is condensed.

20. The composition of claim 19 wherein the composition further comprises a water-miscible solvent.

21. The composition of claim 1 wherein the surfactant is selected from the group consisting of 2, 4, 7, 9-tetramethyl-5-decyn-4, 7-diol, molecules containing an acetylenic diol portion, and blends of 2, 4, 7, 9-tetramethyl-5-decyn-4, 7-diol.

22. The composition of claim 1 wherein the particles further comprise a cell recognition component.

23. The composition of claim 22 wherein the cell recognition component is a ligand, peptide hormone, or an antibody.

24. The composition of claim 23 wherein the cell recognition component comprises tenascin, hyaluronan, or polyvinylpyrrolidone, or a fragment thereof.

25. The composition of claim 24 wherein the average diameter of the particles is less than about 50 nm.

26. The composition of claim 24 wherein the cell recognition component comprises tenascin or a fragment thereof.

27. The composition of claim 1 wherein the average diameter of the particles is less than about 50 nm.

28. The composition of claim 1 wherein the polymer is an iontophoretic polymer.

29. The composition of claim 1 wherein the polymer is a hydrophobic polymer.

30. The composition of claim 1 wherein the polymer is a hydrophilic polymer.

31. The composition of claim 1 wherein the polymer is chosen from the group consisting of polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polyglycolides, polysiloxanes, polyurethanes and copolymers thereof, alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, polymers of acrylic and methacrylic esters, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxy-propyl methyl cellulose, hydroxybutyl methyl cellulose, cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxylethyl cellulose, cellulose triacetate, and cellulose sulphate sodium salt.

32. The composition of claim 1 wherein the polymer is chosen from the group consisting of poly(methyl methacrylate), poly(ethylmethacrylate), poly(butylmethacrylate), poly(isobutylmethacrylate), poly(hexlmethacrylate), poly(isodecylmethacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), polyethylene, polypropylene poly(ethylene glycol), poly(ethylene oxide), and poly(ethylene terephthalate).

33. The composition of claim 1 wherein the polymer is chosen from the group consisting of poly(vinyl alcohols), poly(vinyl acetate, poly vinyl chloride polystyrene, polyvinylpryrrolidone, polyhyaluronic acids, casein, gelatin, glutin, polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates), poly(ethyl methacrylates), poly(butylmethacrylate), poly(isobutylmethacrylate), poly(hexlmethacrylate), poly(isodecl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecl acrylate).

34. The composition of claim 1 wherein the hydrophilic polymer is a member of the group consisting of proteinaceous materials , peptides, carbohydrates.

35. A method of delivering a functional composition across keratinized barrier epithelia to a cell, the method comprising introducing the composition of claim 1 at a position that is separated from the cell by a keratinized barrier epithelium, wherein at least a portion of the plurality of particles passes through the keratinized barrier epithelium to the cell.

36. The method of claim 35 wherein the functional composition is delivered transcutaneously.

37. The method of claim 35 wherein the composition of claim 1 is prepared as a medicament, and the medicament is administered to a patient.

38. A solution comprising the composition of claim 1, the solution comprising a concentration of cations between 20 and 2000 millimolar.

39. The composition of claim 1, further comprising a cation chosen from the group consisting of Ni^{2+}, Mn^{2+}, Mg^{2+}, Ca^{2+}, Al^{3+}, Be^{2+}, Li^{+}, Ba^{2+}, and Gd^{3+}.

40. A medicament comprising the composition of claim 1.

41. The medicament of claim 39 further comprising a form selected from the group consisting of granules, tablets, pellets, films, oral, intravenous, subcutaneous, intraperitoneal, intrathecal, intramuscular, inhalation, topical, transdermal, suppository, pessary, intra urethral, intraportal, intraocular, transtympanic, intrahepatic, intra-arterial, intrathecal, transmucosal, coatings, buccal, and combinations thereof.

42. A method of delivering a functional composition to a patient, the method comprising administering a medicament to the patient that comprises the composition of claim 1.

43. A cell comprising the composition of claim 1, wherein the plurality of particles is associated with the cell.

44. A cell comprising the composition of claim 18, wherein the plurality of particles is associated with the cell.

45. A method of transfecting a cell, the method comprising exposing the cell to the composition of claim 18.

46. A matrix for binding bioactive or diagnostic particles, the matrix comprising the particles of claim 1 and a binder.

47. A method of delivering a medical agent to a cell having caveolae, the method comprising: associating the medical agent with an organic functional composition in

vitro to make an association of the medical agent and the organic functional composition, wherein the assoication is passable through cellular caveolae for delivery of the medical agent.

48. The method of claim 47 wherein the association of the agent and the functional composition comprises a particle.

49. The method of claim 48 wherein the particle has a diameter of less than about 100 nanometers as measured by atomic force microscopy of the particles following drying of the particles.

50. The method of claim 48 wherein the particle has a diameter of less than about 50 nm.

51. The method of claim 48 wherein the particle further comprises a surfactant having an HLB value of less than about 6.0 units.

52. The method of claim 51 wherein the particle has an average diameter of less than about 50 nanometers as measured by atomic force microscopy of the particles following drying of the particles.

53. The method of claim 51 further comprising exposing the particle to the cell.

54. The method of claim 47 wherein the association of the agent and the functional composition has a maximum dimension of no more than about 50 nm nanometers as measured by atomic force microscopy following drying of the association of the agent and the functional composition.

55. The method of claim 47 wherein the functional composition comprises a surfactant.

56. The method of claim 47 further comprising exposing the association of the agent and the functional composition to the cell.

57. The method of claim 47 further comprising administering a medicament to a patient, the medicament comprising the association of the medical agent and the organic functional composition.

58. The method of claim 47 wherein the functional composition comprises a surfactant and a hydrophilic polymer.

59. The method of claim 47 wherein the agent comprises a bioactive component that a member of the group consisting of peptides, proteins, and carbohydrates.

60. The method of claim 47 wherein the agent comprises a member of the group consisting of a bioactive component and a diagnostic agent.

61. The method of claim 47 wherein the agent comprises a fragment of a nucleic acid that comprises a nucleic acid sequence.

62. The method of claim 61 wherein the functional composition comprises a surfactant.

63. The method of claim 47 wherein the association is introduced at a position that is separated from the cell by keratinized barrier epithelia, and the association passes through the keratinized barrier epithelia to the cell.

64. The method of claim 63 further comprising exposing the cell to the association of the agent and the functional composition

65. The method of claim 47 wherein the functional composition comprises carbon and hydrogen.

* * * * *